levodopa has been researched along with Parkinson Disease, Secondary in 613 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 156 (25.45) | 18.7374 |
| 1990's | 242 (39.48) | 18.2507 |
| 2000's | 117 (19.09) | 29.6817 |
| 2010's | 84 (13.70) | 24.3611 |
| 2020's | 14 (2.28) | 2.80 |
| Authors | Studies |
|---|---|
| Dahl, R | 1 |
| Berghauzen-Maciejewska, K; Konieczny, J; Lenda, T; Matłoka, M; Ossowska, K; Pieczykolan, J; Wieczorek, M | 1 |
| Kaneko, S; Kusaka, H; Morise, S; Murakami, A; Nakamura, M; Oki, M; Takenouchi, N; Tohge, R; Yakushiji, Y | 1 |
| Che, NN; Chen, SY; Li, X; Ma, JJ; Yang, HQ | 1 |
| Davies, JS; Elabi, OF; Lane, EL | 1 |
| Chen, X; Dai, F; Jiang, Y; Li, Z; Liu, L; Luo, Y; Mao, T; Shang, Y; Song, J; Sun, T; Tan, D; Tong, X; Zhang, J; Zhou, L | 1 |
| Luan, XQ; Shao, B; Wang, WW; Wang, XS; Wang, XY; Xie, CL; Zhang, XR; Zhang, ZR | 1 |
| Guerrero, MF; López, JL; Olaya, MDP; Vergel, NE; Viña, MD | 1 |
| Chen, SY; He, JC; Wang, WW; Wang, XS; Xie, CL; Zhang, XR; Zhang, ZR | 1 |
| Balogun, CI; Fatoki, AM; Oladimeji, S; Olofinnade, AT; Onaolapo, AY; Onaolapo, OJ; Onaolapo, TM | 1 |
| Bolia, R; Panda, PK; Sharawat, IK; Shrivastava, Y | 1 |
| Bonastre, M; Fuentes, M; Marin, C; Mullol, J | 2 |
| Abdelrahman, A; Ahmed, OG; Mahmoud, ME; Monir, DM; Rehan, IF | 1 |
| Boezwinkle, SA; Collier, TJ; Duffy, MF; Fischer, DL; Manfredsson, FP; Mercado, NM; Mueller, RL; Sandoval, IM; Sortwell, CE; Stancati, JA; Steece-Collier, K | 1 |
| Choi, YK; Go, J; Kim, KS; Lee, CH; Lee, IB; Park, HY; Ryu, YK | 1 |
| Azandeh, SS; Farbood, Y; Ghasemi Dehcheshmeh, M; Jalali, MS; Mansouri, E; Saki, G; Sarkaki, A | 1 |
| Kolmančič, K; Živin, M; Zorovic, M | 1 |
| Di Paolo, T; Morissette, M | 1 |
| Funamizu, Y; Mizukami, H; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T; Yagihashi, S | 1 |
| Alam, M; Grothe, C; Jin, X; Krauss, JK; Ratzka, A; Rumpel, R; Schwabe, K; Tschirner, SK; von Wrangel, C | 1 |
| Bhansali, A; Das, L; Dutta, P; Pal, R | 1 |
| Casteels, C; de Vries, EFJ; Dierckx, RAJO; Doorduin, J; Elsinga, PH; Zhou, X | 1 |
| Cai, J; Li, M; Li, N; Luo, F; Wang, J; Wang, N; Wang, Q; Xiao, H; Xie, Z; Zhang, W | 1 |
| Ai, Y; Andersen, AH; Evans, A; Forman, E; Gash, DM; Grondin, R; Hardy, PA; Yue, G; Yue, J; Zhang, R; Zhang, Z | 1 |
| Jha, RR; Kumar, V; Mittra, N; Patel, DK; Singh, BK; Singh, C; Singh, D; Singh, S | 1 |
| Ivanova, EA; Kapitsa, IG; Pozdnev, VF; Valdman, EA; Voronina, TA; Zolotov, NN | 1 |
| Brys, I; Halje, P; Newman-Tancredi, A; Petersson, P; Scheffer-Teixeira, R; Varney, M | 1 |
| Cui, G; Ding, X; Hua, F; Wang, X; Xiang, J; Yang, X; Zhu, Z | 1 |
| Cenci, MA; Crossman, AR | 1 |
| Beaudoin-Gobert, M; Duperrier, S; Météreau, E; Sgambato, V; Thobois, S; Tremblay, L | 1 |
| Bartlett, MJ; Falk, T; Flores, AJ; Heien, ML; Parent, KL; Polt, R; Porreca, F; Root, BK; Sherman, SJ | 1 |
| Denibaud, AS; Drieu La Rochelle, C; Loiodice, S; Méot, B; Montagne, P; Rion, B; Viel, R; Wing Young, H | 1 |
| Bay, AA; Corcos, DM; Hackney, ME; Hart, AR; Michael Caudle, W | 1 |
| Dixit, A; Mishra, M; Prakash, O; Singh, MP; Singh, PK; Srivastava, G; Verma, D | 1 |
| Bian, JS; Dawe, GS; Del Soldato, P; Hu, LF; Sparatore, A; Tazzari, V; Teo, XQ; Tiong, CX; Xie, L | 1 |
| Barker, RA; Cross, J; Ellul, MA | 1 |
| Factor, SA; Silver, M | 1 |
| Baizabal-Carvallo, JF; Jankovic, J | 1 |
| Carlsson, T; Liss, B; Prinz, A; Roeper, J; Selesnew, LM | 1 |
| Ly, J; Mallela, A; Quik, M; Zhang, D | 1 |
| Chakraborty, J; Dhanasekaran, M; Manivasagam, T; Mohanakumar, KP; Naskar, A; Singh, R; Thomas, B | 1 |
| Bagga, P; Chugani, AN; Patel, AB; Varadarajan, KS | 1 |
| Dominguez-Meijide, A; Garrido-Gil, P; Guerra, MJ; Labandeira-Garcia, JL; Sierrra-Paredes, G; Villar-Cheda, B | 1 |
| Bishop, C; Conti, MM; Dell'isola, R; Goldenberg, AA; Kampton, E; Katzman, AC; Lindenbach, D; Ostock, CY | 1 |
| Caramelli, P; Cardoso, F; Vale, TC | 1 |
| Chae, Y; Choo, HJ; Doo, AR; Kim, SN; Lee, B; Lee, H; Park, HJ; Park, JJ; Park, JY; Shim, I | 1 |
| Carta, M; Collu, M; Fidalgo, C; Gardoni, F; Morelli, M; Stancampiano, R; Tronci, E; Zianni, E | 1 |
| Hattori, T; Karasawa, H; Mogami, S; Taché, Y; Wang, L; Yakabi, K; Yakabi, S; Yamada, C | 1 |
| Downey, P; Michel, A; Nicolas, JM; Scheller, D | 1 |
| Chang, MC; Chun, MH; Kang, CG; Kong, EJ | 1 |
| Bortolanza, M; Del-Bel, E; Issy, AC; Lazzarini, M; Padovan-Neto, FE | 1 |
| Ahmed, MR; Bychkov, E; Dalby, KN; Gurevich, EV; Kook, S; Zurkovsky, L | 1 |
| Ariza, D; Crestani, CC; Dias, DP; Martins-Pinge, MC; Silva, AS | 1 |
| Girault, JA; Hervé, D; Pelosi, A | 1 |
| Harada, N; Kakiuchi, T; Kanazawa, M; Muramatsu, S; Ohba, H; Tsukada, H | 1 |
| Rajput, A; Rajput, AH; Robinson, CA; Shuaib, UA | 1 |
| Bezard, E; Contamin, H; Li, Q; Thiollier, T; Wu, C; Zhang, J | 1 |
| Brauer, AF; Ciucci, MR; Kelm-Nelson, CA | 1 |
| Di Paolo, T; Grégoire, L; Morin, N; Morissette, M; Rajput, A; Rajput, AH | 1 |
| Eskow Jaunarajs, KL; Figge, DA; Standaert, DG | 1 |
| Aguado, C; Lujan, R; Moratalla, R; Solis, O; Suarez, LM | 1 |
| da Costa, AN; Dardou, D; Dremier, S; Durif, F; Hafidi, A; Hanon, E; Loiodice, S; Ouachikh, O; Winlow, P | 1 |
| Breger, LS; Dunnett, SB; Kienle, K; Lane, EL; Smith, GA | 1 |
| Alcacer, C; Andreoli, L; Cenci, MA; Fieblinger, T; Jakobsson, J; Sebastianutto, I | 1 |
| Aguilar, E; Bonastre, M; Marin, C | 1 |
| Aghemo, A; Ballabio, E; Bersano, A; Candelise, L; Colombo, M; Rumi, MG | 1 |
| Emejulu, JK; Malomo, AO | 1 |
| Allbutt, HN; Billing, R; Coster, MJ; Henderson, JM; Kassiou, M; Radford, J; Warraich, ST | 1 |
| Wang, J; Ye, Q; Yuan, CG; Yuan, CX; Zhang, Y | 1 |
| Allbutt, HN; Coster, MJ; Henderson, JM; Kassiou, M; Truong, L | 1 |
| Buck, K; Ferger, B | 1 |
| Frei, K; Truong, DD; Wolters, E | 1 |
| Alcacer, C; Cacciatore, S; Fisone, G; Girault, JA; Greengard, P; Heiman, M; Hervé, D; Santini, E; Valjent, E | 1 |
| Antonini, A; Bovi, T; Fiaschi, A; Moretto, G; Ottaviani, S; Pasquin, I; Steinmayr, M; Tinazzi, M | 1 |
| Abramov, VG; Nesterova, IuV; Pokhabov, DV | 1 |
| Ba, M; Kong, M; Liu, Z; Ma, Y; Song, L | 1 |
| Cao, X; Papa, SM; Qin, K; Xu, Y; Zhang, Z | 1 |
| Chen, JF; Herm, L; Kalda, A; Rinken, A; Zharkovsky, A | 1 |
| Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA | 1 |
| Benamer, HT; Grosset, DG; Kalra, S | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morissette, M; Ouattara, B; Samadi, P | 1 |
| Benazzouz, A; Bioulac, B; De Deurwaerdère, P; Gross, C; Navailles, S | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH; McIldowie, MJ; Piggott, MJ | 1 |
| Baishen, R; Bezard, E; Cenci, MA; Danysz, W; Dekundy, A; Iderberg, H; Li, H; Li, Q; Rylander, D; Zhang, J | 1 |
| Alken, RG; Cenci, MA; Malmlöf, T; Rylander, D; Schilström, B; Schneider, F; Svensson, TH | 1 |
| Jouve, L; Kerkerian-Le Goff, L; Melon, C; Salin, P | 1 |
| Brotchie, JM; Fox, SH | 2 |
| Bakay, RA; Deogaonkar, M; Lieu, CA; Subramanian, T | 1 |
| Cantuti-Castelvetri, I; Crittenden, JR; Graybiel, AM; Hernandez, LF; Hollingsworth, ZR; Keller-McGandy, CE; Kett, LR; Landy, A; Nillni, EA; Saka, E; Standaert, DG; Young, AB | 1 |
| Marin, C; Obeso, JA | 1 |
| Bezard, E; Chan, P; Chen, Z; Dovero, S; Fernagut, PO; Hill, M; Li, Q; Ravenscroft, P; Wu, T | 1 |
| Danysz, W; Dekundy, A; Gravius, A; Hechenberger, M; Mela, F; Nagel, J; Parsons, CG; Pietraszek, M; Tober, C; van der Elst, M | 1 |
| Akaji, K; Akiyama, T; Hiraga, K; Ohira, T; Takao, M; Tanizaki, Y | 1 |
| Brantley, E; Karain, B; Shi, WX; Xu, D | 1 |
| Bishop, C; Button, T; Dupre, KB; Eskow Jaunarajs, KL; Ostock, CY; Savage, LM; Wolf, W | 1 |
| Arami, MA; Ayromlou, H; Najmi, S | 1 |
| Bido, S; Marti, M; Morari, M | 1 |
| Kabuto, H; Yamanushi, TT | 1 |
| Charlton, C; King, JM; Mackey, V; Muthian, G; Smith, M | 1 |
| Chou, KL; Kotagal, V; Patil, PG | 1 |
| Geng, XC; Yin, LL; Zhu, XZ | 1 |
| Chagniel, L; Cyr, M; Lebel, M; Robitaille, C | 1 |
| Gupta, D; Kuruvilla, A | 1 |
| Chao, OY; Huston, JP; Li, JS; Pum, ME | 1 |
| Giuffrida, A; Macheda, T; Martinez, A; Morgese, MG; Trabace, L | 1 |
| Adkins, CE; Cenci, MA; Lockman, PR; Lundblad, C; Ohlin, KE; Sebastianutto, I | 1 |
| Avila, I; Brazhnik, E; Cruz, AV; Gerber, C; Ilieva, NM; McCoy, AJ; Novikov, N; Wahba, MI; Walters, JR | 1 |
| Ahmad, M; Gupta, A; Rizvi, I; Zaidi, N | 1 |
| Kanemaru, A; Kojima, T; Tokashiki, S; Ueda, Y | 1 |
| Cenci, MA; Halje, P; Mohammed, M; Petersson, P; Richter, U; Tamtè, M | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Jarvie, K; Koprich, JB; Lang, AE; Seeman, P | 1 |
| Nakagawasai, O; Nemoto, W; Sato, S; Tadano, T; Tan-no, K; Taniguchi, R; Yamadera, F; Yaoita, F | 1 |
| Brotchie, JM; Nash, JE | 1 |
| Huang, Z; Jacewicz, M; Pfeiffer, RF | 1 |
| Andrén, PE; Gunne, L; Klintenberg, R; Svenningsson, P | 1 |
| Cimini, MG; Haas, JV; Nichols, NF; Staton, BA; Svensson, KA; Tedroff, J | 1 |
| Borra, S; Hauser, RA; Zesiewicz, TA | 1 |
| Di Monte, DA; McCormack, AL | 1 |
| Bankiewicz, KS; Emborg, ME; McLaughlin, WW; Moirano, J; Tetrud, JW | 1 |
| Gu, SD; Sun, XF; Wang, W; Zhao, DZ | 1 |
| Bédard, P; Bélanger, N; Di Paolo, T; Grégoire, L | 1 |
| Gilgun-Sherki, Y; Melamed, E; Offen, D; Ziv, I | 1 |
| Shinohara, Y; Takahashi, H | 1 |
| Furukawa, Y | 1 |
| Colpaert, F; Domino, EF; Marien, M; Ni, L | 1 |
| Decamp, E; Gonczi, H; Schneider, JS | 1 |
| Bédard, PJ; Grégoire, L; Samadi, P | 1 |
| Ceballos-Baumann, A | 1 |
| Archer, T; Fredriksson, A; Schröder, N | 1 |
| Bibbiani, F; Castagnoli, N; Chase, TN; Chen, JF; Oh, JD; Petzer, JP; Schwarzschild, MA | 1 |
| Das, BK; Kalita, J; Misra, UK | 1 |
| Bojko, A; Chutorian, AM; Edelberg, D; Frucht, S; Heier, L; Nygaard, T | 1 |
| Jenner, P | 1 |
| Koller, WC; Lyons, KE; Truly, W | 1 |
| Daniel, SE; Katzenschlager, R; Lees, AJ; Zijlmans, JC | 1 |
| Baba, M; Kannari, K; Kimura, T; Maeda, T; Tanaka, H; Tomiyama, M | 1 |
| Brachet, P; Damier, P; Paillé, V | 1 |
| Ahmed, SM; Chase, TN; Dunbar, GL; Menniti, FS; Oh, JD; Wessell, RH | 1 |
| Bang, OY; Joo, US; Lee, PH; Seo, CH | 1 |
| Djaldetti, R; Lampl, Y; Lorberboym, M; Melamed, E; Sadeh, M | 1 |
| Chu, NS | 1 |
| Felix, R; Kivi, A; Kupsch, A; Niehaus, L; Plotkin, M; Trottenberg, T | 1 |
| Delville, Y; Fleming, SM; Schallert, T | 1 |
| Brotchie, JM; Collingridge, GL; Garner, CC; Johnston, TH; Nash, JE | 1 |
| Turnbull, C | 1 |
| Lo, N; Robinson, T; Thanvi, B | 1 |
| Barone, I; Bernardi, G; Bonsi, P; Calabresi, P; Centonze, D; Picconi, B; Pisani, A | 1 |
| Alvano, A; Battaglia, G; Malaguarnera, M; Raffaele, R; Rampello, L; Vecchio, I | 1 |
| Inoue, H; Taguchi, Y; Takashima, S | 1 |
| Bishop, C; Taylor, JL; Walker, PD | 1 |
| Barak, LS; Beaulieu, JM; Caron, MG; Gainetdinov, RR; Sotnikova, TD; Wetsel, WC | 1 |
| Berk, L; Clackson, T; Cunningham, J; Feng, L; Forsayeth, JR; Rivera, VM; Sanftner, LM; Suzuki, BM; Zhou, S | 1 |
| Bibbiani, F; Chase, TN; Collins, MA; Kielaite, A; Oh, JD; Smith, C | 1 |
| Kadota, S; Li, X; Matsumoto, K; Murakami, Y; Tezuka, Y; Wu, Y | 1 |
| Chen, JF; Schwarzschild, MA; Yu, L | 1 |
| Bankiewicz, KS; Bringas, J; Cunningham, J; Daadi, M; Eberling, JL; Forsayeth, JR; Pivirotto, P; Sanftner, L | 1 |
| Behari, M; Goyal, V; Shukla, G; Singh, S; Srivastava, T | 1 |
| Bontempi, S; Busi, C; Collo, G; Fiorentini, C; Missale, C; Rizzetti, MC; Spano, P | 1 |
| Bernardi, G; Calabresi, P; Centonze, D; Gulino, A; Napolitano, M; Picconi, B | 1 |
| Apaydin, H; Benbir, G; Delil, S; Erginöz, E; Ozekmekçi, S | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M | 1 |
| Schindehütte, J; Trenkwalder, C | 1 |
| Aggarwal, A; Bhatt, M; Desai, S; Shah, S; Singh, J; Vaidya, S | 1 |
| Ba, M; Chen, S; Kong, M; Liu, Z; Lu, G; Ma, G; Yang, H | 1 |
| Alm, H; Andrén, PE; Bezard, E; Crossman, AR; Kultima, K; Lönnstedt, I; Scholz, B; Sköld, K; Svensson, M | 1 |
| Avila, I; Bibbiani, F; Chase, TN; Collins, MA; Oh, JD; Smith, CP | 1 |
| da Silva, EG; Quagliato, EM; Viana, MA | 1 |
| Eskey, CJ; Gardner, TB; Lewis, LD; Nierenberg, DW; Osterling, W; Reddy, NJ | 1 |
| Borsini, F; Carminati, P; Frau, L; Morelli, M; Schintu, N; Simola, N; Tronci, E | 1 |
| Costa, D; Evans, A; Fontes, F; Gacinovic, S; Katzenschlager, R; Lees, AJ; Zijlmans, J | 1 |
| Jing, FC; Wang, DQ; Wang, W | 1 |
| Barbanoj, M; Kulisevsky, J; Pérez, V; Rodríguez-Alvarez, J; Rubio, A; Sosti, V | 1 |
| Dunnett, S; Lane, E | 1 |
| Cassano, T; Cuomo, V; Giuffrida, A; Morgese, MG | 1 |
| Asanuma, M; Hozumi, H; Miyazaki, I; Miyoshi, K; Sogawa, N | 1 |
| Barker, RA; Kuan, WL; Zhao, JW | 1 |
| Andren, PE; Greengard, P; Svenningsson, P; Zhang, X | 1 |
| Bezard, E; Guo, JT; Hengerer, B; Ittrich, C; Li, Q; Nadjar, A; Schuster, S | 1 |
| Müller, T | 1 |
| Barbeau, A | 1 |
| Ananth, J | 1 |
| Shoulson, I | 1 |
| Bitton, V; Melamed, E | 1 |
| Tarsy, D | 1 |
| Baumeister, AA; Breese, GR; Crotty, K; Emerick, SG; Frye, GD; McCown, TJ; Mueller, RA | 1 |
| Blair, RD; Lang, AE | 1 |
| Bergmann, KJ; Mendoza, MR; Moros, D; Yahr, MD | 1 |
| Carlsson, A; Eriksson, T; Granérus, AK; Linde, A; Magnusson, T | 1 |
| Jenner, P; Kelly, E; Kilpatrick, G; Lees, A; Marsden, CD; Rose, S; Rupniak, NM | 1 |
| Csanaky, A; Gyimóti, G; Leposa, D | 1 |
| Dukhovnaia, MA; Evtushenko, SK; Neĭmark, EZ | 1 |
| Ballard, P; Langston, JW | 1 |
| Granérus, AK; Nilsson, NJ; Suurküla, M; Svanborg, A | 1 |
| Agid, Y; Guimaraes, J; Lhermitte, F; Serdaru, M | 1 |
| Kamenetskiĭ, VK | 1 |
| Ayalon, D; Rabey, JM; Ravid, R; Vardi, Y | 1 |
| Antóny, M; Széplaki, Z; Tóth, G | 1 |
| Eventov, I; Geller, E; Moreno, M; Salama, R; Tardiman, R | 1 |
| Fahn, S | 1 |
| Lang, AE; Marsden, CD; Meadows, JC; Parkes, JD | 1 |
| Schunk, W | 1 |
| Meerwaldt, JD; Staal, A | 1 |
| Narabayashi, H | 2 |
| Angelini, L; Broggi, G; Mainini, P; Moretti, G; Nardocci, N | 1 |
| Balík, J; Filip, V; Filipová, M; Janků, I; Krejcová, H; Stika, L; Terziivanov, D | 1 |
| Danielczyk, W | 1 |
| Bertha, G; Lechner, H; Ott, E | 1 |
| Avorn, J; Bohn, RL; Gurwitz, JH; Mogun, H; Monane, M; Walker, A | 1 |
| De Tribolet, N; Ghika, J; Regli, F; Uské, A | 1 |
| Lang, AE | 3 |
| Cardoso, F | 1 |
| Nygaard, TG | 2 |
| Kaur, S; Starr, MS | 1 |
| Lunn, V; Northcott, C; Yatham, LN | 1 |
| Carey, RJ; Dai, H; Huston, JP; Pinheiro-Carrera, M; Schwarting, RK; Tomaz, C | 1 |
| D'Costa, DF; Moore-Smith, B; Phillips, PA; Sheehan, LJ | 1 |
| Agid, Y; Bonnet, AM; Gouider-Khouja, N; Pichon, J; Vidailhet, M | 1 |
| Blin, O; Fabre, N; Montastruc, JL; Rascol, A; Rascol, O; Senard, JM | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Martel, JC; Piercey, MF | 1 |
| Block, F; Clement, HW; Grote, C; Sontag, KH; Wesemann, W | 1 |
| Myers, R; Sawle, GV | 1 |
| Crossman, AR; Page, RD; Sambrook, MA | 1 |
| Boldry, RC; Chase, TN; Engber, TM; Papa, SM | 1 |
| Bösch, MF; Ludin, HP | 1 |
| Carey, RJ; Huston, JP; Pinheiro-Carrera, M; Tomaz, C | 1 |
| Fukuuchi, Y; Kobari, M; Nogawa, S; Obara, K; Shinohara, T | 1 |
| Dotti, MT; Federico, A | 1 |
| Calne, DB; Doudet, D; Hewitt, KA; Nugent, R; Olanow, W; Pate, BD; Perl, DP; Shinotoh, H; Snow, BJ | 1 |
| Carmichael, SW; Cook, JA; Merkel, GJ; Stoddard, SL; Zinsmeister, AR | 1 |
| Ogawa, N | 1 |
| Fukuda, T; Irifune, M; Nomoto, M | 1 |
| Chase, TN; Engber, TM; Kask, AM; Papa, SM | 1 |
| Chutorian, AM; Levine, RA; Naini, AB; Nygaard, TG; Waran, SP | 1 |
| Ball, MC; Sagar, HJ | 1 |
| Gash, DM; Sakai, K | 1 |
| Caligiuri, MP | 1 |
| Agid, Y; Guillen, J; Herrero, MT; Hirsch, EC; Javoy-Agid, F; Kastner, A; Luquin, MR; Obeso, JA | 1 |
| Ferracci, F; Fulgente, T; Ghilardi, MF; Malatesta, G; Onofrj, M | 1 |
| Bankiewicz, KS; de Jesus, S; Sheng, J; Takubo, H; Thomas, J; Wang, J | 1 |
| De Klippel, N; Ebinger, G; Herregodts, P; Michotte, Y; Sarre, S | 1 |
| Bédard, PJ; Blanchet, PJ; Boucher, R | 1 |
| Alexander, GM; Gordon, SW; Grothusen, JR; Schwartzman, RJ | 1 |
| Carey, RJ; Dai, H; Huston, JP; Pinheiro-Carrera, M; Tomaz, C | 1 |
| Bédard, PJ; Blanchette, P; DiPaolo, T; Falardeau, P; Gagnon, C; Gomez-Mancilla, B | 1 |
| Nagatsu, T; Ogawa, M; Suzuki, K; Yoshida, M | 1 |
| Crossman, AR; Graham, WC; Sambrook, MA | 1 |
| Gurevich, V; Jiao, S; Wolff, JA | 1 |
| Blum, S; Jacqmotte, N; Jacquy, J; Mettens, P; Vanderheyden, JE | 1 |
| Kuno, S; Mizuta, E | 1 |
| González, J; Masana, L; Olivé, JM | 1 |
| Agid, Y; Bonnet, AM; Dubois, B; Lefebvre-Caparros, D; Marconi, R; Vidailhet, M | 1 |
| Coutinho, MO; De Albuquerque, ES; Galhardo, I; Medeiros, Lde O | 1 |
| Fouillet, N; Henry, P; Tison, F | 1 |
| Bertolasi, L; Costa, B; Fiaschi, A; Zanette, G | 1 |
| Calne, DB; Hashimoto, S; Hayward, M; Markey, CJ; Markey, SP; Richmond, J; Shinotoh, H; Snow, BJ; Uitti, RJ; Vingerhoets, FJ | 1 |
| Accornero, N; Berardelli, A; Inghilleri, M; Manfredi, M; Priori, A | 1 |
| Eller, RV; Gash, DM; Greenamyre, JT; Kurlan, R; Ovadia, A; Zhang, Z | 1 |
| Amantea, MA; Bravi, D; Chase, TN; Cora-Locatelli, G; Mouradian, MM; Roberts, JW | 1 |
| Dluzen, D; Jain, R; Liu, B | 1 |
| Alexander, GM; Brainard, L; Gordon, SW; Grothusen, JR; Schwartzman, RJ | 2 |
| Fukuda, T; Nomoto, M | 1 |
| Fénelon, G; Feve, A; Guillard, A; Mahieux, F; Romatet, S | 1 |
| Calne, DB; Chu, NS; Hochberg, F; Huang, CC; Lilienfeld, D; Lu, CS; Olanow, W | 1 |
| Broe, GA; Creasey, HM | 1 |
| Ahlskog, JE; Atkinson, EJ; Cha, RH; Maraganore, DM; Muenter, MD; O'Brien, PC; Uitti, RJ | 1 |
| Chase, TN; Engber, TM; Mouradian, MM | 1 |
| Yokochi, M | 1 |
| Furukawa, Y; Kondo, T; Mizuno, Y; Narabayashi, H; Nishi, K | 1 |
| Nomura, Y; Segawa, M | 1 |
| Calne, DB; Nygaard, TG; Snow, BJ; Takahashi, H | 1 |
| Bhatt, MH; Calne, DB; Nakamura, K; Nomoto, M; Okada, A; Osame, M; Snow, BJ | 1 |
| Daniel, SE; Hughes, AJ; Lees, AJ | 1 |
| Imai, H; Kondo, T; Nakamura, T; Narabayashi, H | 1 |
| Björklund, A; Brundin, P; Langston, JW; Lindvall, O; Rehncrona, S; Snow, BJ; Tetrud, J; Widner, H | 1 |
| Gash, DM; Kurlan, R; McDermott, M; Smith, RD; Zhang, Z | 1 |
| Goldhammer, Y; Sadeh, M | 1 |
| Karstaedt, PJ; Pincus, JH | 1 |
| Cole, DG; DiFiglia, M; Growdon, JH | 1 |
| Bösch, S; Kreczy-Kleedorfer, B; Poewe, W; Wagner, M | 1 |
| Agid, Y; Augood, SJ; Emson, PC; Herrero, MT; Hirsch, EC; Javoy-Agid, F; Luquin, MR; Obeso, JA | 1 |
| Misu, Y; Okumura, F; Sato, K; Ueda, H | 1 |
| Brunner-Guenat, M; Carrupt, PA; Jenner, P; Lisa, G; Rose, S; Testa, B; Thomas, K; Ventura, P | 1 |
| Akiyama, K; Ishihara, T; Kashihara, K; Shiro, Y; Shohmori, T | 1 |
| Kulkantrakorn, K; Petruska, PJ; Selhorst, JB | 1 |
| Beal, MF; Calne, DB; Good, PF; Hewitt, KA; Olanow, CW; Perl, DP; Shinotoh, H; Snow, BJ; Vingerhoets, F | 1 |
| Chase, TN; Papa, SM | 1 |
| Agid, Y; Faucheux, B; Herrero, MT; Hirsch, EC; Levy, R; Obeso, JA; Vila, M | 1 |
| López de Munain, A; Martí Massó, JF; Poza, JJ | 1 |
| Agid, Y; Faucheux, B; Guillen, J; Guridi, J; Herrero, MT; Hirsch, EC; Javoy-Agid, F; Levy, R; Luquin, MR; Obeso, JA; Ruberg, M; Villares, J | 1 |
| Arnold, G; Eichhorn, TE; Gasser, T; Mai, N; Marquardt, C; Oertel, WH; Schwarz, J | 1 |
| Keskin, S; Yurdakul, F | 1 |
| Jackson, M; Jenner, P; Marsden, CD; Pearce, RK; Smith, L | 1 |
| Bédard, PJ; Blanchet, PJ; Grondin, R | 1 |
| Hashiguchi, H; Ishida, Y; Kuwahara, I; Mitsuyama, Y; Todaka, K | 1 |
| Folkerts, H; Garrels, L | 1 |
| Bishop, MR; Markopoulou, K; Pavletic, ZS; Wszolek, ZK | 1 |
| Block, F; Nolden-Koch, M; Pergande, G; Purr, J; Schwarz, M | 1 |
| Clouston, PD; Fung, V; Lim, CL; Morris, JG; Yiannikas, C | 1 |
| Hashiguchi, H; Ishida, Y; Kuwahara, I; Mitsuyama, Y; Nishimori, T; Todaka, K | 1 |
| Andersen, AH; Avison, MJ; Chen, Q; Gash, DM; Ovadia, A; Zhang, Z | 1 |
| de Saint-Martin, A; Hirsch, E; Marescaux, C; Picard, F; Salmon, E | 1 |
| Cataneo, EA; Leiguarda, R; Manes, F; Merello, M; Petracca, G; Starkstein, S | 1 |
| Goshima, Y; Misu, Y; Okamura, H; Ueda, H | 1 |
| Benazzouz, A; Bioulac, B; Boraud, T; Burbaud, P; Féger, J; Gross, C | 1 |
| Agid, Y; Asensi, H; Augood, SJ; Emson, PC; Herrero, MT; Hirsch, EC; Obeso, JA | 1 |
| Boldry, RC; Chase, TN; Engber, TM; Kask, AM; Papa, SM | 1 |
| Moses, J; Siddiqui, A; Silverman, PB | 1 |
| Huston, JP; Schwarting, RK | 1 |
| Agid, Y; Faucheux, B; Herrero, MT; Hirsch, EC; Levy, R; Obeso, JA; Ruberg, M; Vila, M | 1 |
| Olanow, CW | 1 |
| Arai, N; Isaji, M; Kojima, M; Kuno, S; Mizuta, E | 1 |
| Abraira, V; Almazán, J; de Pedro-Cuesta, J; Gudmundsson, G; Löve, A; Petersen, IJ; Tulinius, H; Veiga, J | 1 |
| Frohna, PA; Joyce, JN; Rioux, L; Schneider, JS | 1 |
| Aoki, K; Ikeda, K; Kinoshita, M; Tomatsuri, A | 1 |
| Flumerfelt, BA; Newman, DD; Rajakumar, N; Stoessl, AJ | 1 |
| Emerich, DF; Francis, JM; Lindner, MD; Plone, MA | 1 |
| Blaney, TJ; Chandonait, SE; Emerich, DF; Lindner, MD; Mullins, TD; Plone, MA; Sherman, SS; Stott, JA; Winn, SR | 1 |
| Kaur, S; Starr, BS; Starr, MS | 1 |
| Blanchet, PJ; Chase, TN; Metman, LV; Mouradian, MM; Papa, SM | 1 |
| Playfer, JR | 1 |
| Iurasov, VV; Kaplun, VP; Kryzhanovskiĭ, GN; Kucherianu, VG; Nikushkin, EV; Shvets, VI; Zhigal'tsev, IV | 1 |
| Inagaki, T; Ishino, H; Kaku, K; Okunishi, H; Shikimi, T; Takaori, S | 1 |
| Andrén, PE; Ekesbo, A; Gunne, LM; Tedroff, J | 1 |
| Collins, F; Gash, DM; Hilt, D; Kryscio, R; Lapchak, PA; Lebel, C; Miyoshi, Y; Ovadia, A; Zhang, Z | 1 |
| Bédard, PJ; Britton, DR; Grondin, R; Shiosaki, K | 1 |
| Bünger, N; Jeune, B; Joensen, P; Wermuth, L | 1 |
| Iurasov, VV; Kaplun, AP; Kryzhanovskiĭ, GN; Kucherianu, VG; Kudrin, VS; Nikushkin, EV; Podgornyĭ, GI; Sandalov, IuG; Shvets, VI; Zhigal'tsev, IV | 1 |
| Iurasov, VV; Kaplun, AP; Kucherianu, VG; Kudrin, VS; Nikushkin, EV; Sandalov, IuG; Shvets, VI; Zhigal'tsev, IV | 1 |
| Kaizuka, M; Okumura, K; Osawa, H; Shirato, KI; Tamura, N; Tsunoda, S; Yamabe, H | 1 |
| Andringa, G; Cools, AR; Drukarch, B; Stoof, JC; Vermeulen, RJ | 1 |
| Aggarwal, S; Childers, MK; Jimenez, D | 1 |
| Bezard, E; Bioulac, B; Deloire, X; Gross, CE; Imbert, C | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Goulet, M; Morissette, M; Soghomonian, JJ | 1 |
| De Mari, M; Federico, F; Giannini, P; Iliceto, G; Lamberti, P; Lucivero, V; Mezzapesa, DM; Simone, IL; Tarantino, A | 1 |
| Brooks, DJ; Lees, AJ; Pentland, B; Turjanski, N | 1 |
| Quinn, NP | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| Bezard, E; Bioulac, B; Boraud, T; Gross, C; Guehl, D | 1 |
| Brotchie, JM; Crossman, AR; Hill, MP; Hughes, NR; McKnight, AT; Woodruff, GN | 1 |
| Banerji, T; Jenner, P; Marsden, CD; Pearce, RK | 1 |
| Hashitani, T; Kumazaki, M; Mizukawa, K; Nishino, H | 1 |
| Seeman, P; Tallerico, T | 1 |
| Agid, Y; Dziewczapolski, G; García, MC; Gershanik, O; Menalled, LB; Murer, MG; Raisman-Vozari, R | 1 |
| Bernardi, G; Bonci, A; Federici, M; Mercuri, NB; Scarponi, M; Siniscalchi, A | 1 |
| Cohen, LK; Leff, SE; Mandel, RJ; Rendahl, KG; Snyder, RO; Spratt, SK | 1 |
| Golubev, VL; Shtul'man, DR; Shvareva, IS; Veĭn, AM; Zhuchenko, TD | 1 |
| Lapchak, PA | 1 |
| Fitoussi, N; Herzberg, U; Sotnik-Barkai, I; Tornatore, C; Yadid, G | 1 |
| Kang, UJ; Leff, SE; Mandel, RJ; Rendahl, KG; Spratt, SK | 1 |
| Brotchie, JM; Crossman, AR; Henry, B | 2 |
| Lloyd, GK; Menzaghi, F; Pope-Coleman, A; Schneider, JS; Van Velson, M | 1 |
| Domino, EF; Emborg-Knott, ME | 1 |
| Domino, EF; Ni, L | 1 |
| Blanchet, PJ; Chase, TN; Konitsiotis, S | 1 |
| Guerra, MJ; Labandeira-García, JL; López-Martín, E; Rozas, G | 1 |
| Feldon, J; Mintz, M; Mura, A | 2 |
| Haida, M; Kozuma, R; Shinohara, Y; Takagi, S; Takahashi, W; Yoshii, F | 1 |
| Horstink, MW; Jonkman, EJ; Notermans, SL; Pasman, JW; Poortvliet, DJ; Stegeman, DF; van't Hof, MA; Zijlmans, JC | 1 |
| Onofrj, M; Paci, C; Thomas, A | 1 |
| Jain, NK; Jain, SK; Rana, AC | 1 |
| Giladi, N; Melamed, E | 1 |
| Ai, Y; Avison, C; Gash, DM; Zhang, M; Zhang, Z | 1 |
| Fujita, M; Ito, Y; Kusuoka, H; Nishimura, T; Okada, T; Shimada, S; Tohyama, M; Watanabe, Y | 1 |
| Chase, TN; Oh, JD; Vaughan, CL | 1 |
| Arnold, LA; Camp, DM; Hyland, K; Juneau, PL; LeWitt, PA; Loeffler, DA | 1 |
| Bédard, PJ; Doan, VD; Grégoire, L; Grondin, R | 1 |
| Albanese, A; Moro, E | 1 |
| Möller, JC; Oertel, WH; Pogarell, O | 1 |
| Chang, JW; Kang, UJ; Lee, WY; Nemeth, NL | 1 |
| Danysz, W; Karcz-Kubicha, M; Lorenz, B | 1 |
| Damhaut, P; Dethy, S; Goldman, S; Laute, MA | 1 |
| de Bruin, W; Hageman, G; Herholz, K; Steur, EJ; van der Hoek, J; van der Laan, G; van Hout, M | 1 |
| Bédard, PJ; Grégoire, L; Grondin, R; Hadj Tahar, A; Kase, H; Mori, A | 1 |
| Adair, JC; Davis, LE | 1 |
| Prevett, MC; Rossor, MN | 1 |
| Peng, L; Tang, Z; Ying, Q | 1 |
| Andersen, AH; Avison, MJ; Gash, DM | 1 |
| Marin, C; Tolosa, E | 1 |
| de Mattos, JP; Mattos, VM | 1 |
| Domino, EF; Ni, L; Zhang, H | 1 |
| Borbely, K; Brooks, RA; Burns, RS; Cumming, P; Di Chiro, G; Gjedde, A; Wong, DF | 1 |
| Andersen, AH; Avison, MJ; Cass, WA; Chen, Q; Gash, DM; Ovadia, A; Zhang, Z | 1 |
| Blanchet, PJ; Chase, TN; Konitsiotis, S; Whittemore, ER; Woodward, RM; Zhou, ZL | 1 |
| Agid, Y | 1 |
| Bonastre, M; Jiménez, A; Marin, C; Tolosa, E | 1 |
| Sawaishi, Y; Takada, G; Watanabe, Y; Yano, T | 1 |
| Factor, SA; Molho, ES | 1 |
| Aigner, TG; Doudet, D; Fernández-Ruiz, J | 1 |
| Ahlskog, JE | 1 |
| Dunah, AW; Huganir, RL; Kameyama, K; Standaert, DG; Wang, Y; Wolfe, BB; Yasuda, RP | 1 |
| Mandel, RJ | 1 |
| Bezard, E; Bioulac, B; Boraud, T; Gross, CE; Stutzmann, JM | 1 |
| Jackson, MJ; Jenner, P; Kanda, T; Kase, H; Kuwana, Y; Nakamura, J; Pearce, RK; Smith, LA | 1 |
| Di Monte, DA; Jakowec, M; Langston, JW; Petzinger, G; Quik, M | 1 |
| Chase, TN; Oh, JD | 1 |
| Blanchet, PJ; Chase, TN; Konitsiotis, S; Lamers, E; Verhagen, L | 1 |
| Andringa, G; Cools, AR; Drukarch, B; Lubbers, L; Stoof, JC | 1 |
| Chambers, LK; Greenamyre, JT; Jaw-Tsai, SS; Menniti, FS; Steece-Collier, K | 1 |
| Di Monte, DA; Janson, AM; Langston, WJ; McCormack, A; Petzinger, G; Quik, M | 1 |
| Aubert, I; Bezard, E; Fernagut, PO; Ghorayeb, I; Poewe, W; Tison, F; Wenning, GK | 1 |
| Bleich, S; Degner, D; Poser, W; Riegel, A; Rüther, E; Sprung, R | 1 |
| Acarin, N; Benabid, AL; Benazzouz, A; Dowsey, PL; Krack, P; Künig, G; Leenders, KL; Obeso, JA; Pollak, P | 1 |
| Björklund, A; Cenci, MA; Lee, CS; Schulzer, M | 1 |
| Bankiewicz, KS; Bringas, J; Budinger, TF; Cunningham, J; Eberling, JL; Harvey-White, J; Jagust, W; Kohutnicka, M; Pivirotto, P | 1 |
| Bordet, R; Ridray, S; Schwartz, JC; Sokoloff, P | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Hill, MP; Hille, C; Maneuf, Y; McGuire, S; Nash, JE; Peggs, D | 1 |
| Di Monte, DA; He, L; Langston, JW; Quik, M | 1 |
| Koga, K; Kurokawa, M; Kuwana, Y; Nakamura, J; Ochi, M | 1 |
| Kidd, PM | 1 |
| Eidelberg, D; Frucht, SJ; Scarmato, N; Scarmeas, N | 1 |
| Bezard, E; Boraud, T; Brotchie, JM; Chalon, S; Gross, CE; Guilloteau, D | 1 |
| Andrén, PE; Gunne, L; Hurd, YL; Pirker, W; Pontén, H; Tedroff, J | 1 |
| Blunt, SB; Datla, KP; Dexter, DT | 1 |
| Bacheschi, LA; Barbosa, ER; Leiros da Costa, MD; Leite, CC; Scaff, M | 1 |
| Baillet, C; Callizot, N; Guénet, JL; Poindron, P; Warter, JM | 1 |
| Abe, T; Takahashi, S; Tohgi, H; Utsugisawa, K | 1 |
| Bankiewicz, KS; Cunningham, J; Harvey-White, J; Sánchez-Pernaute, R | 1 |
| Andersson, M; Cenci, MA; Konradi, C | 1 |
| Chen, JF; Cuellar, B; Fredduzzi, S; Impagnatiello, F; Monopoli, A; Moratalla, R; Ongini, E; Schwarzschild, MA; Xu, K | 1 |
| Andersson, M; Cenci, MA; Kirik, D; Lundblad, M; Wierup, N; Winkler, C | 1 |
| Boesch, SM; Poewe, W; Ransmayr, G; Wenning, GK | 1 |
| Aggarwal, A; Ling, MJ; Morris, JG | 1 |
| Kaku, DA; Sarasombath, P; Sumida, K | 1 |
| Kaumeier, S | 1 |
| Halbhübner, K; Herken, H; Loos, D | 1 |
| Marttila, RJ; Rinne, UK; Siirtola, T; Sonninen, V | 1 |
| Seyfert, S; Straschill, M | 1 |
| Marsden, CD | 1 |
| Halbhübner, K; Herken, H; Kehr, W; Loos, D | 1 |
| Battista, AF; Goldstein, M; Lew, JY; Lieberman, A; Matsumoto, Y | 1 |
| Borison, RL; Diamond, BI | 1 |
| Finn, BW; Mendez, JS | 1 |
| Caine, ED; Davis, GC; Ebert, MH; Kopin, IJ; Markey, SP; Reichert, CM; Williams, AC | 1 |
| Morel-Maroger, A | 1 |
| Durand, JP; Gautier, JC | 1 |
| Godwin-Austen, RB | 1 |
| Del Pesce, M; Di Bella, P; Forastieri, L; Paggi, A; Quattrini, A | 1 |
| Fischer, PA; Jacobi, P; Schneider, E | 1 |
| Albizzati, MG; Frattola, L; Scarlato, G; Trabucchi, M | 1 |
| De Ryck, M; Ramirez, VD; Schallert, T; Teitelbaum, P; Whishaw, IQ | 1 |
| Bathien, N; Rondot, P | 1 |
| Agostini, L; Firenze, C; Gallai, V; Piccinin, GL; Piccirilli, M; Rossi, A | 1 |
| Matsui, T; Matsuoka, Y; Muroga, T; Sugimura, K; Wakayama, Y | 1 |
| Granérus, AK | 1 |
| Agnoli, A; Denaro, A; Lelli, A; Ruggieri, S | 1 |
| Petelin, LS; Zograbian, AS | 1 |
| Poirier, LJ | 1 |
| Filion, M; Larochelle, L; Péchadre, JC; Poirier, LJ | 1 |
| Babucke, G; Mertz, DP; Sagebiel, L | 1 |
| Binder, H; Gerstenbrand, F; Grünberger, J; Gründig, E; Schubert, H | 1 |
| Lizogub, VG; Man'kovskii, NB; Vanishtok, AB | 1 |
| Carolei, A; Casacchi, M; Fazio, C | 1 |
| Neundörfer, B; Valdivieso, T | 1 |
| Snyder, SH | 1 |
| Becker, H; Bohn-Schwarz, G; Fischer, PA; Jacobi, P; Schneider, E | 1 |
| Aunis, D; Collard, M; Coquillat, G; Mandel, P; Miras Portugal, MT; Rohmer, F; Warter, JM | 1 |
| Kadykov, AS | 1 |
| Piccirilli, M; Quartesan, R | 1 |
| Dolezalová, B; Vacek, J | 1 |
| Evtushenko, SK | 1 |
| Völler, GW | 1 |
| Brody, JA; Kurland, LT; Stanhope, JM | 1 |
| Marsden, CD; Parkes, JD; Tarsy, D | 1 |
| Girke, W; Xenakis, Ch | 1 |
| Deze, J; Völler, GW | 1 |
| Keichian, AH; Oliver, RE; Rivera, VM | 1 |
| Duvoisin, RC; Jenner, P; Marsden, CD; Parkes, JD; Pycock, C; Tarsy, D | 1 |
| Pelfréne, AF | 1 |
| Wiesel, FA | 1 |
| Godwin-Austen, R | 1 |
| Golubev, VL; Iakhno, NN; Veĭn, AM | 1 |
| Hornykiewicz, VO | 1 |
| Ballivet, J; Boudry, C; Gisselmann, A; Marin, A | 1 |
| Quinn, NP; Steiger, MJ | 1 |
| García de Yébenes, J; García Urra, D; García-Ruiz, PJ; Jiménez-Jiménez, FJ; Morales, B; Vázquez, A | 1 |
| Gershanik, O; Luquin, MR; Obeso, JA; Scipioni, O; Vaamonde, J | 1 |
| Camarata, PJ; Chae, H; Ebner, TJ; Haines, SJ; Park, SK; Parker, RG; Turner, DA | 1 |
| Foster, AC; Hill, RG; Iversen, L; Iversen, SD; Kemp, JA; Leeson, PD; Rupniak, NM; Saywell, K; Tricklebank, MD; Williams, BJ | 1 |
| Close, SP; Elliott, PJ; Walsh, DM | 1 |
| Charlton, CG; Crowell, B | 1 |
| Di Chiara, G; Fenu, S; Morelli, M | 1 |
| Dethlefsen, J; Vieregge, P | 1 |
| Björklund, A; Brundin, P; Gustavii, B; Langston, JW; Lindvall, O; Rehncrona, S; Snow, B; Tetrud, J; Widner, H | 1 |
| Dubas, F; Henin, D; Vidailhet, M | 1 |
| Bédard, PJ; Gomez-Mancilla, B | 2 |
| Huppert, D; Soyka, M | 1 |
| Jansen, EN; Kölling, P | 1 |
| Aquilonius, SM; Bjurling, P; Hartvig, P; Långström, B; Lundqvist, H; Tedroff, J | 1 |
| Page, RD | 1 |
| Lieberman, A | 1 |
| Chen, S | 1 |
| Abercrombie, ED; Hastings, TG; Zigmond, MJ | 1 |
| Boyce, S; Iversen, SD; Marsden, CD; Rupniak, NM; Steventon, MJ | 1 |
| Arai, N; Goshima, Y; Misu, Y; Misugi, K | 1 |
| Gash, DM; Greenamyre, JT; Honoré, T; Klockgether, T; Kurlan, R; Turski, L; Zhang, ZM | 1 |
| Lu, CS; Tsai, CH | 1 |
| Balottin, U; Borgatti, R; Lanzi, G; Zambrino, CA | 1 |
| Abbott, RJ; D'Costa, DF; Millac, PA; Pye, IF | 1 |
| Ashwood, TJ; Bateman, DN; Tulloch, JA; Woodhouse, KW | 1 |
| Honoré, T; Jähnig, P; Jenner, P; Kunow, M; Lange, KW; Löschmann, PA; Marsden, CD; Rettig, KJ; Turski, L; Wachtel, H | 1 |
| Hughes, AJ; Lees, AJ; Stern, GM | 1 |
| Montastruc, JL; Rascol, A; Rascol, O; Senard, JM | 1 |
| Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ; Tye, S | 1 |
| Di Chiara, G; Morelli, M | 1 |
| Close, SP; Elliott, PJ; Hayes, AG; Marriott, AS | 1 |
| Montastruc, JL | 1 |
| Nagatsu, T; Niwa, T; Yoshida, M | 1 |
| Bankiewicz, KS; Cogan, DG; Hogan, N; Kopin, IJ; Oldfield, EH; Plunkett, RJ; Schuette, WH; Zuddas, A | 1 |
| Gash, DM; Kim, MH; Kurlan, R | 1 |
| Bodis-Wollner, I; Chung, E; Ghilardi, MF; Glover, A; Onofrj, M; Pasik, P; Samson, Y | 1 |
| Baas, H; Fischer, PA | 1 |
| Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ | 1 |
| Burke, RE; Fahn, S; Giladi, N; Gordon, M; Hunt, A; Kostic, V; Przedborski, S | 1 |
| Fujitake, J; Kuno, S; Mizuta, E | 1 |
| Pletscher, A | 1 |
| Garnett, ES; Lang, AE | 1 |
| Bédard, PJ; Di Paolo, T; Rouillard, C | 1 |
| Archer, T; Fredriksson, A; Sundström, E | 1 |
| Boyce, S; Clarke, CA; Crossman, AR; Robertson, RG; Sambrook, MA | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Luquin, R; Mitchell, IJ; Peggs, D; Robertson, RG; Sambrook, MA | 1 |
| Ransom, BR; Trosch, RM | 1 |
| Boyce, S; Iversen, SD; Rupniak, NM; Steventon, M | 1 |
| Bakheit, AM; Henderson, LM; Moore, AP; Simpson, JA; Thomas, M | 1 |
| Berger, HJ; Horstink, MW; Korten, JJ; Pasman, JW; van 't Hof, MA; Zijlmans, JC | 1 |
| Caraceni, T; Cesana, BM; Geminiani, G; Giovannini, P; Girotti, F; Scigliano, G; Soliveri, P | 1 |
| Bar, M; Graff, E; Isakov, M; Oberman, Z; Rabey, JM; Scharf, M | 1 |
| Bédard, P; Boucher, R; Daigle, M; Di Paolo, T | 1 |
| Lewin, R | 2 |
| Langston, JW; Tetrud, JW | 2 |
| Agid, Y; Bonnet, AM; Jenner, PG; Lataste, X; Markstein, R; Marsden, CD; Pourcher, E; Quinn, NP; Temlett, JA | 1 |
| Schneider, JS | 1 |
| Iversen, SD; Miyaji, M; Naruse, T; Rupniak, NM; Tye, SJ | 1 |
| Yoshida, M | 1 |
| Boyce, S; Crossman, AR; Luquin, MR; Peggs, D; Sambrook, MA | 1 |
| Campanella, G; De Michele, G; Filla, A; Mengano, A; Trombetta, L | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Robertson, RG; Sambrook, MA | 2 |
| Caraceni, T; Lamperti, E; Lorizio, A; Nordera, N | 1 |
| Bovingdon, M; Frankel, JP; Kempster, PA; Lees, AJ; Stern, GM; Webster, R | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Sambrook, MA | 1 |
| Chen, SD; Pan, GB; Xu, DL; Yu, WC | 1 |
| Hirose, Y; Kajita, S; Mizukawa, K; Ogawa, N; Ohara, S; Watanabe, Y | 1 |
| Annable, L; Chouinard, G; Mercier, P; Turnier, L | 1 |
| Casabona, J; Jankovic, J | 1 |
| Hardie, RJ; Lees, AJ | 1 |
| Bathien, N; Fournier, V; Morselli, PL; Rondot, P; Ziegler, M | 1 |
| Critchley, P; Grandas, F; Marsden, CD; Quinn, N; Rohan, A; Stahl, SM | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Sambrook, MA; Stahl, SM | 1 |
| De Cuypere, G; Jannes, C; Remouchamps, A; Tack, E | 1 |
| Jankovic, J | 1 |
| Jenner, P; Marsden, CD | 1 |
| Finberg, JP; Youdim, MB | 1 |
| Kondo, T; Nagatsu, T; Narabayashi, H; Yokochi, F | 1 |
| Jörg, J; Schneider, I | 1 |
| Bioulac, B; Doudet, D; Gross, C; Lebrun-Grandié, P | 2 |
| Bayer, AJ; Day, JJ; Finucane, P; Pathy, MS | 1 |
| Burns, RS; Crane, AM; Ho, VW; Kopin, IJ; Porrino, LJ; Sokoloff, L | 1 |
| Mizukawa, K; Ogawa, N; Sora, YH | 1 |
| Bodis-Wollner, I; Ghilardi, MF; Glover, AA; Marx, MS; Onofrj, MC | 1 |
| Domino, EF; Greenberg, HS; Hood, TW | 1 |
| Calne, DB; Guttman, M; Kebabian, JC; Mak, E; Pate, BD; Wolters, EC | 1 |
| Kondo, T; Narabayashi, H; Nishi, K | 1 |
| Grundmann, M; Schimrigk, K | 1 |
| Perquin, WV; Van Leeuwen, RB | 1 |
| Brown, RG; Gotham, AM; Marsden, CD; Nissenbaum, H; Quinn, NP; Toone, B | 1 |
| Lieberman, AN | 2 |
| Bankiewicz, KS; Chiueh, CC; Doppman, JL; Jacobowitz, DM; Kopin, IJ; Oldfield, EH | 1 |
| Bédard, PJ; Boucher, R; Di Paolo, T; Falardeau, P | 1 |
| Williams, A | 1 |
| Carlsson, A | 1 |
| Clarke, CE; Crossman, AR; Mitchell, IJ; Sambrook, MA | 1 |
| Bakay, RA; Barrow, DL; Collins, DC; Fiandaca, MS; Iuvone, PM; Schiff, A | 1 |
| Burns, RS; Crane, AM; Kopin, IJ; Palombo, E; Porrino, LJ; Sokoloff, L | 1 |
| Duvoisin, RC; Sage, JI | 1 |
| Luque, FA; Petruska, P; Selhorst, JB | 1 |
| Kamenetskiĭ, VK; Nuller, IuL | 1 |
| Godlevskiĭ, LS; Kryzhanovskiĭ, GN; Makul'kin, RF; Rozhkov, VS; Shandra, AA | 1 |
| Gauthier, L; Gauthier, S | 1 |
| el-Awar, M; Freedman, M; Goldenberg, L; Little, J; Seeman, P; Solomon, P | 1 |
| Kadykov, AS; Pivovarova, VM; Shvedkov, VV; Stoliarova, LG | 1 |
| Clarenbach, P; Fröscher, W | 1 |
| Fischer, PA | 1 |
| Widhalm, S | 1 |
| Jonsson, G; Mefford, I; Schultz, W; Studer, A; Sundström, E | 1 |
| Hirose, Y; Ogawa, N; Ohara, S; Ono, T; Watanabe, Y | 1 |
| Backlund, EO; Freed, W; Herrera-Marschitz, M; Hoffer, B; Olson, L; Seiger, A; Strömberg, I | 1 |
| Close, SP; Marriott, AS; Pay, S | 1 |
| Jaeckle, RS; Nasrallah, HA | 1 |
| Espadaler Medina, JM | 1 |
| Gillingham, FG; Tsukamoto, Y | 1 |
| Barone, G; Carotti, A; Lucciarini, L; Mugnai, A; Tomassetti, G | 1 |
| Fischer, GJ; Quandt, J; Sommer, H | 1 |
| Chase, TN | 1 |
| Baumann, N; Castaigne, P; Rondot, P; Taberlet, A | 1 |
| Ljungberg, T; Steg, G; Ungerstedt, U | 1 |
63 review(s) available for levodopa and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Non-human primate models of PD to test novel therapies.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 2018 |
Animal models of l-dopa-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary | 2018 |
Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review.
Topics: Age Factors; Antiparkinson Agents; Brain; Cerebrovascular Disorders; Diagnosis, Differential; Dopamine Plasma Membrane Transport Proteins; Gait; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Tremor | 2010 |
The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Basal Ganglia; Cognition Disorders; Disease Models, Animal; Dopamine; Drug Discovery; Endpoint Determination; Humans; Levodopa; Movement; MPTP Poisoning; Neurons; Neuroprotective Agents; Parkinson Disease, Secondary; Primates; Psychoses, Substance-Induced; Sleep Wake Disorders | 2010 |
Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Levodopa; Parkinson Disease, Secondary | 2010 |
Vascular parkinsonism: what makes it different?
Topics: Antiparkinson Agents; Brain Ischemia; Dementia; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease, Secondary | 2011 |
[Diagnosis and therapy for patients with vascular parkinsonism].
Topics: Akinetic Mutism; Amantadine; Antiparkinson Agents; Cerebral Infarction; Dementia, Vascular; Diagnosis, Differential; Gait Disorders, Neurologic; Humans; Levodopa; Muscle Rigidity; Parkinson Disease, Secondary; Platelet Aggregation Inhibitors; Posture; Secondary Prevention; Tremor | 2003 |
Update on dopa-responsive dystonia: locus heterogeneity and biochemical features.
Topics: Antiparkinson Agents; Brain Chemistry; Dystonia; Family Health; Genetic Heterogeneity; Genetic Linkage; GTP Cyclohydrolase; Humans; Levodopa; Motor Activity; Mutation; Parkinson Disease, Secondary; Phenylketonurias; Tyrosine 3-Monooxygenase | 2004 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inhibitors; Clinical Trials as Topic; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Enzyme Inhibitors; Ergot Alkaloids; Family Practice; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Piperidines | 2003 |
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Dopamine Agonists; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Nitriles; Parkinson Disease, Secondary; Primates; Rats | 2004 |
Vascular parkinsonism--an important cause of parkinsonism in older people.
Topics: Aged; Antiparkinson Agents; Brain; Cerebral Infarction; Diagnostic Imaging; Humans; Intracranial Arteriosclerosis; Levodopa; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Risk Factors; Treatment Outcome | 2005 |
Pathological synaptic plasticity in the striatum: implications for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cerebral Cortex; Denervation; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Potentiation; Neostriatum; Neuronal Plasticity; Parkinson Disease; Parkinson Disease, Secondary; Rats; Synapses | 2005 |
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; MPTP Poisoning; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Reproducibility of Results; Sympatholytics | 2008 |
Role of homocysteine in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Brain; Catechol O-Methyltransferase; Homocysteine; Humans; Levodopa; Parkinson Disease, Secondary | 2008 |
Current psychopathological theories of tardive dyskinesia and their implications for future research.
Topics: Acetylcholine; Adult; Aged; Animals; Antipsychotic Agents; Brain; Dopamine; Dyskinesia, Drug-Induced; Estrogens; Female; gamma-Aminobutyric Acid; Haplorhini; Humans; Levodopa; Norepinephrine; Parkinson Disease, Secondary; Rats; Receptors, Dopamine; Tyrosine 3-Monooxygenase | 1982 |
Movement disorders with neuroleptic drug treatment.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Diagnosis, Differential; Dopamine; Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Huntington Disease; Levodopa; Neuroleptic Malignant Syndrome; Parasympatholytics; Parkinson Disease, Secondary; Receptors, Dopamine; Time Factors; Tourette Syndrome | 1984 |
Parkinson's disease in 1984: an update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Dementia; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Primates; Psychoses, Substance-Induced; Pyridines; Receptors, Dopamine; Time Factors | 1984 |
Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome.
Topics: Antiparkinson Agents; Blood Glucose; Carbidopa; Contrast Media; Deoxyglucose; Dihydroxyphenylalanine; Dominance, Cerebral; Drug Combinations; Female; Fluorodeoxyglucose F18; Functional Laterality; Hemiplegia; Humans; Levodopa; Middle Aged; Muscle Hypotonia; Muscular Atrophy; Neurologic Examination; Parkinson Disease, Secondary; Physical Exertion; Substantia Nigra; Tomography, Emission-Computed | 1995 |
[Treatment of Parkinson disease].
Topics: Antiparkinson Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Treatment Failure | 1995 |
Dopa-responsive dystonia.
Topics: Child, Preschool; Chromosome Aberrations; Chromosome Disorders; Corpus Striatum; Diagnosis, Differential; DNA Mutational Analysis; Dystonia; Genes, Dominant; GTP Cyclohydrolase; Humans; Infant; Levodopa; Neural Pathways; Parkinson Disease, Secondary; Phenotype; Spinal Cord; Substantia Nigra | 1995 |
The role of positron emission tomography in the assessment of human neurotransplantation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Basal Ganglia; Brain Tissue Transplantation; Caudate Nucleus; Fetal Tissue Transplantation; Fluorine Radioisotopes; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Parkinson Disease; Parkinson Disease, Secondary; Putamen; Tomography, Emission-Computed; Transplantation, Heterotopic; Treatment Outcome | 1993 |
Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages.
Topics: Animals; Brain; Bromocriptine; Corpus Striatum; Dopamine Agonists; Free Radicals; Humans; Levodopa; Mice; Parkinson Disease; Parkinson Disease, Secondary; Premedication; Reactive Oxygen Species; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission | 1994 |
[Parkinson disease induced by flunarizine: report of a case].
Topics: Biperiden; Female; Flunarizine; Humans; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1993 |
Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.
Topics: Animals; Chorea; Corpus Striatum; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Levodopa; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Receptors, Dopamine | 1993 |
Nosological concept of juvenile parkinsonism with reference to the dopa-responsive syndrome.
Topics: Activities of Daily Living; Adolescent; Adult; Brain; Diagnosis, Differential; Female; Humans; Levodopa; Male; Movement Disorders; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary | 1993 |
Hereditary progressive dystonia with marked diurnal fluctuation. Pathophysiological importance of the age of onset.
Topics: Adolescent; Adult; Age Factors; Basal Ganglia; Brain Stem; Child; Circadian Rhythm; Dystonia; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Parkinson Disease, Secondary; Sex Factors; Sleep Stages | 1993 |
Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis.
Topics: Adolescent; Adult; Child; Diagnosis, Differential; Dystonia; Female; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Phenotype | 1993 |
[Drug treatment of frequent disorders in patients with Parkinson's disease].
Topics: Anticonvulsants; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Calcium Channel Blockers; Depressive Disorder; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Tranquilizing Agents | 1996 |
Neurobiology of L-DOPAergic systems.
Topics: Afferent Pathways; Animals; Antiparkinson Agents; Brain Stem; Cardiovascular Physiological Phenomena; Central Nervous System; Corpus Striatum; Disease Models, Animal; Humans; Hypothalamus; Levodopa; Models, Neurological; Motor Activity; Neurons; Neurotransmitter Agents; Parkinson Disease; Parkinson Disease, Secondary; Pressoreceptors; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Neurotransmitter | 1996 |
The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.
Topics: Animals; Antiparkinson Agents; Brain; Dopamine Agonists; Functional Laterality; Humans; Levodopa; Motor Activity; Neurotoxins; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Stereotyped Behavior | 1996 |
Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action.
Topics: 1-Methyl-4-phenylpyridinium; Antioxidants; Apoptosis; Clinical Trials as Topic; Dopamine; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Prospective Studies; Randomized Controlled Trials as Topic; Selegiline | 1996 |
Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Motor Activity; Parkinson Disease, Secondary; Rats; Stimulation, Chemical | 1997 |
Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Excitatory Amino Acid Antagonists; Levodopa; Movement; Parkinson Disease, Secondary; Rats; Receptors, N-Methyl-D-Aspartate | 1997 |
Parkinson's disease.
Topics: Aged; Aging; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1997 |
Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
Topics: Antipsychotic Agents; Binding, Competitive; Cholinergic Antagonists; Clozapine; Corpus Striatum; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Resistance; Dyskinesia, Drug-Induced; Humans; Levodopa; Ligands; Limbic System; Nerve Tissue Proteins; Parkinson Disease, Secondary; Protein Binding; Psychoses, Substance-Induced; Psychotic Disorders; Radioligand Assay; Receptors, Dopamine D2; Receptors, Muscarinic; Receptors, Serotonin; Recurrence; Serotonin Antagonists; Tomography, Emission-Computed | 1998 |
A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; Drug Evaluation, Preclinical; Drug Therapy, Combination; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Nerve Growth Factors; Nerve Regeneration; Nerve Tissue Proteins; Neuroglia; Neuronal Plasticity; Parkinson Disease, Secondary; Substantia Nigra; Tyrosine 3-Monooxygenase | 1998 |
Apomorphine and levodopa challenge in patients with a focal midbrain lesion.
Topics: Adult; Antiparkinson Agents; Apomorphine; Brain Damage, Chronic; Female; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease, Secondary; Treatment Outcome | 1999 |
[The diagnosis of the parkinsonian syndrome].
Topics: Antiparkinson Agents; Apomorphine; Brain; Diagnosis, Differential; Humans; Levodopa; Parkinson Disease, Secondary; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1999 |
[New dopaminergic agonists].
Topics: Antiparkinson Agents; Dopamine Agonists; Dopamine Antagonists; Humans; Levodopa; Parkinson Disease, Secondary | 1999 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
Investigating levodopa-induced dyskinesias in the parkinsonian primate.
Topics: Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary; Primates | 2000 |
Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
Topics: Animals; Corpus Striatum; Dopamine Agents; Humans; Levodopa; Motor Neurons; Parkinson Disease; Parkinson Disease, Secondary | 2000 |
Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management.
Topics: Disease Progression; Electron Transport; Humans; Levodopa; Mitochondria; Neurodegenerative Diseases; Oxidation-Reduction; Parkinson Disease, Secondary; Parkinsonian Disorders | 2000 |
The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias).
Topics: Acetylcholine; Animals; Biogenic Amines; Brain; Brain Chemistry; Butyrophenones; Corpus Striatum; Dopamine; Dystonia Musculorum Deformans; Humans; Huntington Disease; Levodopa; Movement Disorders; Parkinson Disease; Parkinson Disease, Secondary; Phenothiazines; Serotonin; Tourette Syndrome; Tranquilizing Agents | 1975 |
The treatment of Parkinson's disease.
Topics: Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1977 |
[Vascular parkinsonism (a review)].
Topics: Basal Ganglia; Brain; Catecholamines; Cerebral Hemorrhage; Cerebrovascular Disorders; Humans; Hypertension; Intracranial Arteriosclerosis; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1975 |
Physiopathology of experimental Parkinsonism in the monkey.
Topics: Animals; Cerebellum; Corpus Striatum; Disease Models, Animal; Dopamine; Haplorhini; Levodopa; Motor Cortex; Movement Disorders; Muscle Rigidity; Neural Pathways; Olivary Nucleus; Parkinson Disease, Secondary; Red Nucleus; Substantia Nigra; Tremor | 1975 |
[Progress in therapy of Parkinsonian syndrome].
Topics: Amantadine; Carboxy-Lyases; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease, Secondary; Postoperative Care; Stereotaxic Techniques; Sympathomimetics | 1975 |
Patterns of Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia on Guam.
Topics: Adult; Aged; Amines; Amyotrophic Lateral Sclerosis; Autopsy; Dementia; Demography; Environmental Pollutants; Ethnicity; Female; Gene Frequency; Guam; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Toxins, Biological | 1975 |
[Side-effects of L-dopa therapy].
Topics: Arrhythmias, Cardiac; Basal Ganglia Diseases; Depression; Female; Gastrointestinal Diseases; Humans; Hypotension, Orthostatic; Levodopa; Male; Nausea; Parkinson Disease, Secondary; Psychoses, Substance-Induced; Sex Factors; Time Factors; Vomiting | 1975 |
Neurotoxin-related research: from the laboratory to the clinic.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Mice; MPTP Poisoning; Nervous System; Neurotoxins; Oxazines; Parkinson Disease, Secondary; Prodrugs; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Saimiri | 1992 |
The use of thalamotomy in the treatment of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Stereotaxic Techniques; Thalamus | 1992 |
Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.
Topics: Animals; Brain; Dopamine; Humans; Levodopa; Neurons; Neurotoxins; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats | 1992 |
Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
Topics: Administration, Oral; Aged; Apomorphine; Drug Evaluation; False Negative Reactions; Humans; Injections, Subcutaneous; Levodopa; Middle Aged; Parkinson Disease, Secondary; Probability | 1990 |
[Slowing the progression of Parkinson syndrome by early administration of deprenyl].
Topics: Animals; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Selegiline | 1990 |
Levodopa treatment of Parkinson's syndrome: past and future.
Topics: Benserazide; Brain; Carboxy-Lyases; Drug Therapy, Combination; Forecasting; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine | 1990 |
Dopamine agonists and antagonists in the treatment of idiopathic dystonia.
Topics: Animals; Circadian Rhythm; Dopamine; Dopamine Antagonists; Dystonia; Humans; Levodopa; Parkinson Disease, Secondary | 1988 |
Parkinson's disease: recent advances in therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Antiparkinson Agents; Carbidopa; Dopamine; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Pyridines | 1988 |
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine; Ergolines; Humans; Levodopa; Macaca mulatta; Neural Pathways; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Saimiri; Selegiline; Species Specificity; Substantia Nigra | 1986 |
MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Deoxyglucose; Haplorhini; Humans; Levodopa; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Spiperone | 1987 |
[A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzylamines; Dopamine; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Norepinephrine; Parkinson Disease, Secondary; Pyridines | 1987 |
Transplantation of monoamine-producing cell systems in oculo and intracranially: experiments in search of a treatment for Parkinson's Disease.
Topics: Adrenal Medulla; Amines; Animals; Brain; Chromaffin System; Denervation; Disease Models, Animal; Dopamine; Electrophysiology; Epinephrine; Eye; Female; Graft Survival; Hippocampus; Humans; Levodopa; Locus Coeruleus; Male; Middle Aged; Nerve Fibers; Nerve Growth Factors; Nerve Tissue; Neurons; Norepinephrine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Receptors, Dopamine; Substantia Nigra | 1985 |
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extrapyramidal Tracts; Fenclonine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Imipramine; Levodopa; Muscular Diseases; Paralysis; Parkinson Disease; Parkinson Disease, Secondary; Probenecid; Reserpine; Serotonin; Spinal Cord Diseases; Tetrabenazine; Time Factors | 1974 |
28 trial(s) available for levodopa and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Effect of levodopa treatment for parkinsonism in welders: A double-blind study.
Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Humans; Levodopa; Male; Manganese Poisoning; Middle Aged; Parkinson Disease, Secondary; Welding | 2004 |
123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cerebrovascular Disorders; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Organometallic Compounds; Parkinson Disease, Secondary; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 2004 |
Does fluoxetine aggravate Parkinson's disease? A pilot prospective study.
Topics: Aged; Drug Therapy, Combination; Female; Fluoxetine; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Pilot Projects; Prospective Studies; Treatment Outcome | 1995 |
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
Topics: Adolescent; Adult; Aged; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Synergism; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease, Secondary; Placebos; Tolcapone | 1993 |
Aspartame use in Parkinson's disease.
Topics: Aged; Aspartame; Humans; Levodopa; Middle Aged; Parkinson Disease, Secondary; Phenylalanine | 1993 |
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E | 1996 |
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E | 1996 |
Drug-induced parkinsonism in schizophrenic patients: motor response and psychiatric changes after acute challenge with L-Dopa and apomorphine.
Topics: Adult; Analysis of Variance; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Cross-Over Studies; Double-Blind Method; Female; Humans; Levodopa; Motor Activity; Parkinson Disease, Secondary; Psychiatric Status Rating Scales; Schizophrenia | 1996 |
EEG findings in patients with vascular parkinsonism.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Cerebrovascular Disorders; Diagnosis, Differential; Electroencephalography; Female; Gait; Humans; Levodopa; Male; Parkinson Disease; Parkinson Disease, Secondary | 1998 |
Apomorphine and levodopa challenge in patients with a focal midbrain lesion.
Topics: Adult; Antiparkinson Agents; Apomorphine; Brain Damage, Chronic; Female; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease, Secondary; Treatment Outcome | 1999 |
Experimental and clinical studies on bromocriptine in the Parkinsonian syndrome.
Topics: Animals; Bromocriptine; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; Ergot Alkaloids; Haplorhini; Humans; Levodopa; Parkinson Disease, Secondary; Rats; Receptors, Adrenergic, alpha; Receptors, Dopamine | 1978 |
[Treatment of parkinsonian syndromes by bromocriptin].
Topics: Aged; Amantadine; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Humans; Hypotension; Levodopa; Male; Movement Disorders; Nausea; Parkinson Disease, Secondary | 1977 |
[Efficacy and side-effects of long term L-dopa therapy in Parkinsonian syndromes (evaluated by CT scan as well) (author's transl)].
Topics: Adult; Benserazide; Brain; Carbidopa; Clinical Trials as Topic; Confusion; Electrocardiography; Electroencephalography; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Stomach Diseases; Tomography, X-Ray Computed | 1979 |
Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Metoclopramide; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Parkinson Disease, Secondary; Pimozide; Placebos; Promethazine | 1975 |
[Treatment of Parkinson's syndrome using a new preparation from the series of tricyclic psychotropic drugs].
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Dibenzazepines; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease, Secondary | 1975 |
Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Female; Fetal Tissue Transplantation; Humans; Immunosuppression Therapy; Levodopa; Male; Mesencephalon; Motor Activity; Parkinson Disease, Secondary; Putamen; Stereotaxic Techniques; Time Factors; Tomography, Emission-Computed | 1992 |
A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients.
Topics: Aged; Benserazide; Carbidopa; Chlormethiazole; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Sleep Initiation and Maintenance Disorders; Sleep Stages; Temazepam | 1991 |
Levodopa treatment of Parkinson's syndrome: past and future.
Topics: Benserazide; Brain; Carboxy-Lyases; Drug Therapy, Combination; Forecasting; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine | 1990 |
Long-term double masked trial of early treatment with L-dopa plus bromocriptine versus L-dopa alone in Parkinson's disease. Interim results.
Topics: Bromocriptine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1990 |
Big first scored with nerve diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Designer Drugs; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline; Substantia Nigra | 1989 |
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Random Allocation; Selegiline | 1989 |
A double-blind, cross-over trial with madopar HBS in patients with Parkinson's disease.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary | 1989 |
Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms.
Topics: Adult; Antipsychotic Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Procyclidine; Pyrrolidines; Schizophrenia | 1987 |
Therapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias.
Topics: Adult; Aged; Antipsychotic Agents; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Placebos | 1987 |
R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Models, Theoretical; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Pyridines; Selegiline | 1987 |
Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia.
Topics: Aged; Aged, 80 and over; Benserazide; Biological Availability; Capsules; Consumer Behavior; Deglutition Disorders; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Random Allocation; Tablets | 1988 |
Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial.
Topics: Aged; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Muscle Rigidity; Parkinson Disease; Parkinson Disease, Secondary; Tremor | 1987 |
Clinical trial for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Levodopa; Models, Neurological; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinson Disease, Secondary; Prospective Studies; Pyridines; Pyridinium Compounds; Selegiline | 1985 |
524 other study(ies) available for levodopa and Parkinson Disease, Secondary
| Article | Year |
|---|---|
A new target for Parkinson's disease: Small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats.
Topics: Aminoquinolines; Animals; Benzamides; Calcium; Cell Death; Drug Discovery; Dyskinesias; Endoplasmic Reticulum Stress; Enzyme Activators; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2017 |
Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; GABAergic Neurons; Humans; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats; Severity of Illness Index | 2021 |
Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; GABAergic Neurons; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; RNA-Binding Proteins; Serotonergic Neurons; Serotonin Agents; Zonisamide | 2021 |
Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.
Topics: Adult; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antiparkinson Agents; Autoantibodies; Benserazide; Cognitive Dysfunction; Drug Combinations; Fever of Unknown Origin; Handwriting; Humans; Immunosuppressive Agents; Immunotherapy; Levodopa; Male; Methylprednisolone; Neuropsychological Tests; Parkinson Disease, Secondary; Tremor | 2021 |
L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease.
Topics: Animals; Cell Movement; Corpus Striatum; Dopaminergic Neurons; Drug Interactions; Embryo, Mammalian; Exenatide; Female; Gene Expression; Glucagon-Like Peptide-1 Receptor; Graft Survival; Insulin Resistance; Leukocytes; Levodopa; Liraglutide; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2021 |
Lycium barbarum polysaccharide improves dopamine metabolism and symptoms in an MPTP-induced model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Disease Models, Animal; Dopamine; Drugs, Chinese Herbal; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 2022 |
Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats.
Topics: Adenoviridae; Animals; Antiparkinson Agents; beta-Arrestin 2; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Gene Deletion; Genetic Therapy; Genetic Vectors; Levodopa; Male; MAP Kinase Signaling System; Neostriatum; Parkinson Disease, Secondary; Phosphoproteins; Rats; Rats, Sprague-Dawley; Recovery of Function; Transcription Factors | 2019 |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Haloperidol; Levodopa; Locomotion; Male; Mice; Mice, Inbred ICR; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Reserpine | 2019 |
β-arrestin2 alleviates L-dopa-induced dyskinesia via lower D1R activity in Parkinson's rats.
Topics: Adenoviridae; Animals; beta-Arrestin 2; Gene Expression Regulation; Gene Knockdown Techniques; Levodopa; Male; Parkinson Disease, Secondary; Rats; Receptors, Dopamine D1 | 2019 |
An Evaluation of the Effects of Pyridoxal Phosphate in Chlorpromazineinduced Parkinsonism using Mice.
Topics: Animals; Antioxidants; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Body Weight; Carbidopa; Chlorpromazine; Diet; Drug Combinations; Eating; Grooming; Levodopa; Lipid Peroxidation; Mice; Motor Activity; Parkinson Disease, Secondary; Pyridoxal Phosphate | 2020 |
Case Report: Dengue Virus-Triggered Parkinsonism in an Adolescent.
Topics: Adolescent; Antiparkinson Agents; Brain; Carbidopa; Dengue; Diffusion Magnetic Resonance Imaging; Drug Combinations; Electroencephalography; Humans; India; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary; Treatment Outcome | 2020 |
Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Pramipexole; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction | 2020 |
Globus pallidus, but not entopeduncular nucleus, 6-OHDA-induced lesion attenuates L-Dopa-induced dyskinesia in the rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Globus Pallidus; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction | 2020 |
Forced exercise activates the NrF2 pathway in the striatum and ameliorates motor and behavioral manifestations of Parkinson's disease in rotenone-treated rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Gait Disorders, Neurologic; Levodopa; Male; Memory, Short-Term; Movement Disorders; Neostriatum; NF-E2-Related Factor 2; Parkinson Disease, Secondary; Physical Conditioning, Animal; Psychomotor Performance; Rats; Rats, Wistar; Rotenone; Signal Transduction; Tyrosine 3-Monooxygenase; Uncoupling Agents; Up-Regulation | 2020 |
The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cell Transplantation; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Dyskinesias; Embryo, Mammalian; Gene Knock-In Techniques; Levodopa; Mesencephalon; Oxidopamine; Parkinson Disease, Secondary; Rats; Sympatholytics; Vesicular Glutamate Transport Protein 2 | 2021 |
β‑Lapachone ameliorates L‑DOPA‑induced dyskinesia in a 6‑OHDA‑induced mouse model of Parkinson's disease.
Topics: Animals; Dyskinesias; Levodopa; Male; Mice; Naphthoquinones; Oxidopamine; Parkinson Disease, Secondary | 2021 |
Therapeutic effects of Wharton's jelly-derived Mesenchymal Stromal Cells on behaviors, EEG changes and NGF-1 in rat model of the Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Dopaminergic Neurons; Drug Combinations; Electroencephalography; Insulin-Like Growth Factor I; Levodopa; Male; Medial Forebrain Bundle; Mesenchymal Stem Cell Transplantation; Motor Activity; Nerve Growth Factor; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Substantia Nigra; Wharton Jelly | 2021 |
Effects of L-dopa on expression of prolactin and synaptotagmin IV in 17-beta-estradiol-induced prolactinomas of ovariectomized hemiparkinsonian rats.
Topics: Animals; Estradiol; Female; Levodopa; Ovariectomy; Parkinson Disease, Secondary; Pituitary Gland; Prolactin; Prolactinoma; Rats; Rats, Wistar; Synaptotagmins | 2021 |
Morphological dendritic spine changes of medium spiny neurons in the nucleus accumbens in 6-hydroxydopamine-lesioned rats treated with levodopa.
Topics: Animals; Apomorphine; Dendritic Spines; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Medial Forebrain Bundle; Neurons; Nucleus Accumbens; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Statistics, Nonparametric; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2017 |
Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
Topics: Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Glutamate Decarboxylase; Levodopa; Motor Cortex; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, GABA; RNA, Messenger; Sympatholytics; Tandem Mass Spectrometry | 2017 |
Secondary parkinsonism in a patient of psychogenic polydipsia.
Topics: Adult; Antiparkinson Agents; Contrast Media; Humans; Levodopa; Magnetic Resonance Imaging; Male; Myelinolysis, Central Pontine; Parkinson Disease, Secondary; Polydipsia, Psychogenic; Treatment Outcome | 2017 |
Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease, Secondary; Positron-Emission Tomography; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Dopamine D2; Sympatholytics | 2017 |
Granger causality supports abnormal functional connectivity of beta oscillations in the dorsolateral striatum and substantia nigra pars reticulata in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Beta Rhythm; Corpus Striatum; Disease Models, Animal; Electroencephalography Phase Synchronization; Levodopa; Male; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Pars Reticulata; Rats; Rats, Sprague-Dawley | 2017 |
Objectively measuring effects of electro-acupuncture in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Electroacupuncture; Female; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Motor Activity; Motor Cortex; Parkinson Disease; Parkinson Disease, Secondary | 2018 |
Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease.
Topics: alpha-Synuclein; Animals; Levodopa; Male; Parkinson Disease, Secondary; Proteasome Endopeptidase Complex; Protein Aggregates; Rats; Rats, Wistar; Ubiquitin; Zinc | 2018 |
[Effect of afobazole and levodopa on the activity of proline-specific proteinases and adenosine deaminase in blood serum and brain structures of rats with experimental Parkinson's syndrome induced by systemic administration of rotenone].
Topics: Adenosine Deaminase; Animals; Benzimidazoles; Brain; Dipeptidyl Peptidase 4; Levodopa; Morpholines; Parkinson Disease, Secondary; Proline; Prolyl Oligopeptidases; Rats; Rotenone; Serine Endopeptidases; Serum | 2017 |
Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT
Topics: Animals; Basal Ganglia; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesias; Electric Stimulation; Evoked Potentials; Female; Levodopa; Neural Pathways; Parkinson Disease, Secondary; Piperazines; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thalamus | 2018 |
CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; PC12 Cells; Protein Kinase Inhibitors; Rats; Signal Transduction; Sulfonamides; Sympatholytics; Tyrosine 3-Monooxygenase | 2018 |
Pathophysiology of levodopa-induced dyskinesia: Insights from multimodal imaging and immunohistochemistry in non-human primates.
Topics: Animals; Brain; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Macaca fascicularis; MPTP Poisoning; Multimodal Imaging; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Fibers; Parkinson Disease, Secondary; Positron-Emission Tomography; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins | 2018 |
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dizocilpine Maleate; Drug Synergism; Dyskinesia, Drug-Induced; Glycopeptides; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats | 2018 |
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; Forelimb; Gait Disorders, Neurologic; Interpersonal Relations; Levodopa; Locomotion; Male; Maze Learning; Memory Disorders; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2019 |
The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Female; Functional Laterality; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Severity of Illness Index | 2019 |
Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Homeodomain Proteins; Levodopa; Male; Maneb; Metalloporphyrins; Mice; Microglia; Minocycline; Mitochondria; Paraquat; Parkinson Disease, Secondary; Proteome; Stathmin; Superoxide Dismutase | 2013 |
Therapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat model.
Topics: Animals; Antioxidants; Antiparkinson Agents; Cell Line, Tumor; Cell Survival; Disulfides; Dopamine; Dopaminergic Neurons; Enzyme Induction; Gene Expression; Glutamate-Cysteine Ligase; Heme Oxygenase-1; Humans; Levodopa; Lipid Peroxidation; Male; Oxidative Stress; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Response Elements; Substantia Nigra | 2013 |
L-dopa responsive parkinsonism secondary to a subdural haematoma.
Topics: Antiparkinson Agents; Female; Hematoma, Subdural; Humans; Levodopa; Middle Aged; Parkinson Disease, Secondary | 2013 |
Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Valproic Acid | 2013 |
Deep brain stimulation of the subthalamic nucleus for peripherally induced parkinsonism.
Topics: Adult; Antiparkinson Agents; Cholinergic Antagonists; Combined Modality Therapy; Deep Brain Stimulation; Disease Progression; Dopamine Agonists; Drug Resistance; Drug Therapy, Combination; Humans; Levodopa; Magnetic Resonance Imaging; Male; Neuronal Plasticity; Pallidotomy; Parkinson Disease, Secondary; Severity of Illness Index; Shoulder Injuries; Subthalamic Nucleus | 2014 |
Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Levodopa; Male; Mice; Oxidopamine; Parkinson Disease, Secondary; Raphe Nuclei; Serotonergic Neurons; Serotonin | 2013 |
Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Cotinine; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; Female; Levodopa; Male; MPTP Poisoning; Nicotine; Nicotinic Agonists; Parkinson Disease, Secondary; Saimiri | 2013 |
Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism.
Topics: Animals; Antiparkinson Agents; Central Nervous System Depressants; Corpus Striatum; Dendrites; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Melatonin; Mice; Mice, Inbred BALB C; MPTP Poisoning; Parkinson Disease, Secondary | 2013 |
In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: recovery of cerebral metabolism with acute levodopa treatment.
Topics: Acetates; Algorithms; Animals; Antiparkinson Agents; Blood Glucose; Brain Chemistry; Energy Metabolism; Glutamates; Hand Strength; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neostriatum; Oxidation-Reduction; Parkinson Disease, Secondary; Psychomotor Performance; Radiopharmaceuticals | 2013 |
Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Corpus Striatum; Disease Models, Animal; Dopamine; Levodopa; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats; Receptor, Serotonin, 5-HT1B; Receptors, Dopamine; Serotonin; Tetrazoles | 2014 |
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Citalopram; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2014 |
Vascular parkinsonism: a case series of 17 patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Cerebrovascular Disorders; Cognition Disorders; Cross-Sectional Studies; Female; Humans; Hypertension; Levodopa; Male; Parkinson Disease, Secondary; Risk Factors; Surveys and Questionnaires; Treatment Outcome | 2013 |
Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of L-dopa by normalizing Parkinson's disease-induced neurochemical imbalance.
Topics: Acupuncture Therapy; Animals; Antiparkinson Agents; Brain Chemistry; Combined Modality Therapy; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Movement; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Substantia Nigra | 2014 |
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Acid Antagonists; Levodopa; Male; Memantine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2014 |
Preventive effect of rikkunshito on gastric motor function inhibited by L-dopa in rats.
Topics: Animals; Carbidopa; Drugs, Chinese Herbal; Gastric Emptying; Ghrelin; Levodopa; Male; Oligopeptides; Parkinson Disease, Secondary; Postprandial Period; Rats, Sprague-Dawley; Receptors, Ghrelin | 2014 |
Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Benzothiazoles; Drug Therapy, Combination; Levodopa; Mass Spectrometry; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Purines; Pyrimidines; Rats; Receptors, N-Methyl-D-Aspartate; Triazoles | 2014 |
Parkinsonism after external ventricular drainage in a patient with intraventricular hemorrhage.
Topics: Activities of Daily Living; Carbidopa; Caudate Nucleus; Cerebral Ventricles; Drainage; Drug Combinations; Female; Humans; Intracranial Hemorrhages; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease, Secondary; Positron-Emission Tomography; Predictive Value of Tests; Putamen; Radiopharmaceuticals; Recovery of Function; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tropanes; Ventriculoperitoneal Shunt | 2015 |
Disturbance of sensorimotor filtering in the 6-OHDA rodent model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Humans; Levodopa; Male; Mice; Oxidopamine; Parkinson Disease, Secondary; Prepulse Inhibition; Rats; Rats, Wistar | 2015 |
Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.
Topics: Animals; Cell Nucleus; Cytosol; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; G-Protein-Coupled Receptor Kinases; Levodopa; Mitogen-Activated Protein Kinases; Neostriatum; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Signal Transduction | 2015 |
Cardiovascular and autonomic alterations in rats with Parkinsonism induced by 6-OHDA and treated with L-DOPA.
Topics: Animals; Antiparkinson Agents; Autonomic Nervous System; Baroreflex; Biogenic Monoamines; Blood Pressure; Dopamine; Heart Rate; Hemodynamics; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Sympatholytics | 2015 |
Unilateral Lesion of Dopamine Neurons Induces Grooming Asymmetry in the Mouse.
Topics: Animals; Dopamine Agents; Dopaminergic Neurons; Functional Laterality; Grooming; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Parkinson Disease, Secondary | 2015 |
Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Topics: Animals; Brain; Carbidopa; Dihydroxyphenylalanine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Enzyme Inhibitors; Levodopa; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Presynaptic; Tyrosine | 2016 |
Neuroleptic-induced Parkinsonism: Clinicopathological study.
Topics: Aged; Antipsychotic Agents; Dopamine Agents; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Parkinson Disease, Secondary; Substantia Nigra | 2016 |
Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Brain; Disease Models, Animal; Dopamine; Levodopa; Macaca; Male; Parkinson Disease; Parkinson Disease, Secondary; Permeability; Pyridines | 2016 |
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Communication Disorders; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Combinations; Fourier Analysis; Levodopa; Male; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Stereotyped Behavior; Time Factors; Ultrasonics; Vocalization, Animal | 2016 |
Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiparkinson Agents; Bungarotoxins; Case-Control Studies; Caudate Nucleus; Corpus Striatum; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Gene Expression; Humans; Iodine Radioisotopes; Levodopa; Macaca fascicularis; Male; Organ Specificity; Ovariectomy; Parkinson Disease; Parkinson Disease, Secondary; Putamen; Pyridines; Signal Transduction | 2016 |
Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Dioxygenases; Disease Models, Animal; DNA Methylation; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitors; GADD45 Proteins; Gene Expression Regulation; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Phthalimides; Rats; Rats, Sprague-Dawley; Tryptophan | 2016 |
L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Female; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Spine; Sympatholytics | 2016 |
Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Benzothiazoles; Corpus Striatum; Dopamine; Female; Humans; Impulsive Behavior; Levodopa; Male; Parkinson Disease, Secondary; Pramipexole; Rats; Receptor, Metabotropic Glutamate 5 | 2017 |
Influence of chronic L-DOPA treatment on immune response following allogeneic and xenogeneic graft in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Transplantation; Combined Modality Therapy; Female; Graft Survival; Immunity, Active; Levodopa; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2017 |
Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.
Topics: Animals; Humans; Levodopa; Mice; Mice, Transgenic; Neural Pathways; Neurons; Parkinson Disease, Secondary; Rats; Receptor, Muscarinic M3; Receptors, Dopamine D2; Visual Cortex | 2017 |
Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Denervation; Dopamine Plasma Membrane Transport Proteins; Hydroxydopamines; Immunohistochemistry; Levodopa; Locus Coeruleus; Male; Movement; Neostriatum; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Substantia Nigra; Tyrosine 3-Monooxygenase | 2008 |
Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism.
Topics: Antiparkinson Agents; Antiviral Agents; Benserazide; Drug Therapy, Combination; Humans; Interferon alpha-2; Interferon-alpha; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2008 |
Could Parkinsonism complicate craniotomy and excision of convexity meningioma? A case report.
Topics: Antiparkinson Agents; Brain Neoplasms; Craniotomy; Hematoma; Humans; Intracranial Hemorrhages; Levodopa; Male; Meningioma; Middle Aged; Parkinson Disease, Secondary; Postoperative Hemorrhage; Tomography, X-Ray Computed | 2008 |
Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
Topics: Administration, Oral; Adrenergic Agents; Animals; Antiparkinson Agents; Benzamidines; Disease Models, Animal; Dopamine; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Immunohistochemistry; Levodopa; Medial Forebrain Bundle; Motor Activity; Neurons; Oxidopamine; Parkinson Disease, Secondary; Postural Balance; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Tyrosine 3-Monooxygenase | 2009 |
[Effects of traditional Chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine D2 receptor in corpora striatum of rats with levodopa-induced dyskinesias].
Topics: Animals; Benserazide; Corpus Striatum; Drugs, Chinese Herbal; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Phytotherapy; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2008 |
Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.
Topics: Administration, Oral; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Excitatory Amino Acid Antagonists; Female; Immunohistochemistry; Intralaminar Thalamic Nuclei; Levodopa; Medial Forebrain Bundle; N-Methylaspartate; Neurons; Oxidopamine; Parkinson Disease, Secondary; Postural Balance; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Rotation; Tyrosine 3-Monooxygenase | 2009 |
Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Analysis of Variance; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Microdialysis; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Severity of Illness Index | 2009 |
Case studies in the advancement of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary | 2008 |
L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice.
Topics: Animals; Antiparkinson Agents; Blotting, Western; Dyskinesias; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Receptors, Dopamine D1; Receptors, Dopamine D2; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Substantia Nigra; Sympatholytics | 2009 |
Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Dopamine Plasma Membrane Transport Proteins; Female; Follow-Up Studies; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease, Secondary; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tropanes | 2009 |
[Rehabilitation of gait disorders in patients with Parkinson's disease and vascular parkinsonism].
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Exercise Therapy; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary | 2009 |
Inhibitory effect of 8-(3-chlorostryryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats.
Topics: Adenosine A2 Receptor Agonists; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Dopamine and cAMP-Regulated Phosphoprotein 32; Levodopa; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Motor Activity; Movement; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Signal Transduction; Up-Regulation | 2009 |
Quantitative autoradiographic study on receptor regulation in the basal ganglia in rat model of levodopa-induced motor complications.
Topics: Animals; Autoradiography; Basal Ganglia; Gene Expression Regulation; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate | 2009 |
Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Benzazepines; Caffeine; Corpus Striatum; Dopamine Agonists; Drug Therapy, Combination; Guanosine 5'-O-(3-Thiotriphosphate); Levodopa; Lisuride; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Random Allocation; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulfur Radioisotopes | 2009 |
Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dynorphins; Dyskinesias; Electron Transport Complex IV; Enkephalins; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus | 2009 |
Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Autoradiography; Biogenic Amines; Brain Chemistry; Catecholamines; Caudate Nucleus; Data Interpretation, Statistical; Dopamine Plasma Membrane Transport Proteins; Female; In Situ Hybridization; Levodopa; Macaca fascicularis; MPTP Poisoning; Ovariectomy; Oximes; Parkinson Disease, Secondary; Putamen; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Reserpine; RNA, Messenger | 2010 |
High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Extracellular Space; Hippocampus; Hydroxyindoleacetic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinson Disease, Secondary; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin 5-HT1 Receptor Agonists; Subthalamic Nucleus | 2010 |
Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Piperidines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Thiazoles | 2010 |
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca mulatta; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate | 2010 |
Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias.
Topics: Analysis of Variance; Animals; Autoradiography; Brain; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Statistics, Nonparametric; Treatment Outcome; Tyrosine 3-Monooxygenase | 2010 |
Deep brain stimulation of the center median-parafascicular complex of the thalamus has efficient anti-parkinsonian action associated with widespread cellular responses in the basal ganglia network in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Denervation; Disease Models, Animal; Electron Transport Complex IV; Feedback, Sensory; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus; Tachykinins; Thalamus | 2010 |
Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Carotid Arteries; Conditioning, Operant; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonia; Female; Injections, Intravenous; Levodopa; Macaca mulatta; MPTP Poisoning; Parkinson Disease, Secondary; Psychomotor Performance; Radionuclide Imaging; Radiopharmaceuticals; Substantia Nigra | 2011 |
Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Thyrotropin-Releasing Hormone | 2010 |
Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Female; Levodopa; Macaca mulatta; Parkinson Disease, Secondary; Protein Binding; Tomography, Emission-Computed, Single-Photon | 2010 |
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Allosteric Regulation; Analysis of Variance; Animals; Brain; Calcium; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Fear; In Vitro Techniques; Levodopa; Male; Maze Learning; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Pain Measurement; Parkinson Disease, Secondary; Picolinic Acids; Psychomotor Performance; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Tandem Mass Spectrometry; Time Factors | 2011 |
Severe parkinsonism following endoscopic third ventriculostomy for non-communicating hydrocephalus--case report.
Topics: Antiparkinson Agents; Cerebral Hemorrhage; Endoscopy; Humans; Hydrocephalus; Image Processing, Computer-Assisted; Intracranial Arteriovenous Malformations; Levodopa; Magnetic Resonance Imaging; Male; Neurologic Examination; Parkinson Disease, Secondary; Postoperative Complications; Radiosurgery; Recurrence; Reoperation; Third Ventricle; Tomography, X-Ray Computed; Ventriculostomy; Young Adult | 2011 |
Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
Topics: Animals; Apomorphine; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Electrophysiological Phenomena; Evoked Potentials; GABA Agonists; Levodopa; Male; Muscimol; Neurons; Parkinson Disease, Secondary; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Substantia Nigra | 2011 |
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Benzazepines; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Male; Microdialysis; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists | 2011 |
Hemiparkinsonism-hemiatrophy syndrome.
Topics: Adult; Antiparkinson Agents; Atrophy; Benzothiazoles; Biperiden; Carbidopa; Cerebral Cortex; Cerebral Ventricles; Dopamine Agonists; Drug Combinations; Humans; Indans; Levodopa; Magnetic Resonance Imaging; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Pramipexole; Tomography, X-Ray Computed | 2011 |
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Glutamates; Hydroxydopamines; Levodopa; Male; Mice; Microdialysis; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2011 |
Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl)phenol] on the pathological progress in the 6-hydroxydopamine-induced Parkinson's disease mouse model.
Topics: Animals; Antioxidants; Ascorbic Acid; Catalase; Corpus Striatum; Disease Models, Animal; Dopamine; Eugenol; Free Radical Scavengers; Glutathione; Glutathione Peroxidase; Guaiacol; Levodopa; Male; Mice; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Superoxide Dismutase | 2011 |
L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dopamine; Female; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 2011 |
Motor improvement with bilateral subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive secondary parkinsonism.
Topics: Deep Brain Stimulation; Female; Humans; Levodopa; Measles-Mumps-Rubella Vaccine; Middle Aged; Motor Skills; Parkinson Disease, Secondary; Subthalamic Nucleus; Treatment Outcome | 2012 |
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benserazide; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RGS Proteins | 2011 |
Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Calpain; Corpus Striatum; Cyclin-Dependent Kinase 5; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2012 |
The grid-walking test: assessment of sensorimotor deficits after moderate or severe dopamine depletion by 6-hydroxydopamine lesions in the dorsal striatum and medial forebrain bundle.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Uptake Inhibitors; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Nervous System Diseases; Oxidopamine; Parkinson Disease, Secondary; Psychomotor Performance; Rats; Rats, Wistar; Sympatholytics; Walking | 2012 |
The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.
Topics: Animals; Behavior, Animal; Benzoxazines; Cannabinoids; Cyclic AMP-Dependent Protein Kinases; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Levodopa; Male; Morpholines; Motor Activity; Naphthalenes; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Rats; Rats, Wistar | 2012 |
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
Topics: Algorithms; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Benserazide; Blood-Brain Barrier; Capillaries; Cerebrovascular Circulation; Dyskinesias; Female; Glucose; Immunohistochemistry; Intermediate Filament Proteins; Levodopa; Nerve Tissue Proteins; Nestin; Oxidopamine; Parkinson Disease, Secondary; Permeability; Rats; Rats, Sprague-Dawley; Sympatholytics; Tyrosine 3-Monooxygenase | 2012 |
State-dependent spike and local field synchronization between motor cortex and substantia nigra in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Cortical Synchronization; Data Interpretation, Statistical; Dopamine; Dopamine Antagonists; Electrodes, Implanted; Electroencephalography; Electromyography; Levodopa; Male; Membrane Potentials; Motor Activity; Motor Cortex; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rest; Substantia Nigra; Walking | 2012 |
Isolated extra pontine myelinolysis presenting as acute onset parkinsonism.
Topics: Acute Disease; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Middle Aged; Myelinolysis, Central Pontine; Parkinson Disease, Secondary; Saline Solution, Hypertonic | 2012 |
Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Gene Expression; Gene Expression Profiling; Isoxazoles; Levodopa; Male; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Zonisamide | 2012 |
Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations.
Topics: Algorithms; Animals; Antiparkinson Agents; Cerebral Cortex; Dyskinesia, Drug-Induced; Electrodes, Implanted; Electroencephalography; Evoked Potentials; Female; Fluorescent Antibody Technique; Levodopa; Microelectrodes; Neostriatum; Neurons; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Tyrosine 3-Monooxygenase | 2012 |
The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Butyrophenones; Cloning, Molecular; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary; Psychoses, Substance-Induced | 2013 |
Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Bromocriptine; Calcium; Catalepsy; Dopamine Agonists; Food, Formulated; Levodopa; Magnesium; Magnesium Deficiency; Male; Mice; Parkinson Disease, Secondary; Receptors, Dopamine; Risk Factors; Substantia Nigra; Tyrosine 3-Monooxygenase | 2013 |
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Microinjections; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Piperidines; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2002 |
Anticardiolipin antibody in vascular parkinsonism.
Topics: Aged; Antibodies, Anticardiolipin; Antiparkinson Agents; Brain; Brain Ischemia; Cerebrovascular Circulation; Cognition Disorders; Female; Gait; Humans; Levodopa; Lower Extremity; Male; Neuropsychological Tests; Parkinson Disease, Secondary; Posture; Risk Factors | 2002 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Narcotic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; RNA; Rotation; Stereotyped Behavior; Sympathectomy, Chemical | 2002 |
PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Homovanillic Acid; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Quinpirole; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Sympathectomy, Chemical; Sympatholytics | 2002 |
Clozapine withdrawal symptoms in a Parkinson's disease patient.
Topics: Aged; Antipsychotic Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Substance Withdrawal Syndrome | 2002 |
Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration.
Topics: Amino Acids; Animals; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Paraquat; Parkinson Disease, Secondary; Substantia Nigra; Tyrosine 3-Monooxygenase | 2003 |
Rest tremor in rhesus monkeys with MPTP-induced parkinsonism.
Topics: Animals; Female; Levodopa; Macaca mulatta; Male; MPTP Poisoning; Parkinson Disease, Secondary; Tremor | 2003 |
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Dopamine; Drug Combinations; Drug Synergism; Drugs, Chinese Herbal; Homovanillic Acid; Levodopa; Male; Mice; Parkinson Disease, Secondary; Plant Extracts; Plants, Medicinal; Reserpine | 2002 |
Estradiol and dehydroepiandrosterone potentiate levodopa-induced locomotor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dehydroepiandrosterone; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Female; Functional Laterality; Levodopa; Macaca fascicularis; Motor Activity; Ovariectomy; Parkinson Disease, Secondary | 2003 |
Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Riluzole; Synaptic Transmission | 2003 |
Effects of (+/-)-idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys.
Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Idazoxan; Levodopa; Macaca nemestrina; Parkinson Disease, Secondary; Time Factors | 2003 |
Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Appetite; Behavior, Animal; Blinking; Dopamine Agents; Dyskinesia, Drug-Induced; Facial Expression; Feeding Behavior; Levodopa; Macaca fascicularis; Male; Motor Activity; Motor Skills; Parkinson Disease, Secondary; Postural Balance; Posture; Time Factors; Tremor | 2003 |
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Endorphins; Female; Levodopa; Macaca fascicularis; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission | 2003 |
Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Basal Ganglia; Brain; Brain Chemistry; Dopamine Agents; Female; Iron; Iron Overload; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease, Secondary; Prefrontal Cortex; Pregnancy; Weight Gain | 2003 |
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Apomorphine; Denervation; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Purines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Dopamine D1; Receptors, Dopamine D2; Sympatholytics | 2003 |
Sporadic variety of pallido-pyramidal syndrome.
Topics: Adult; Antiparkinson Agents; Female; Globus Pallidus; Humans; Levodopa; Parkinson Disease, Secondary; Pyramidal Tracts; Radionuclide Imaging; Syndrome | 2003 |
Toxic pediatric parkinsonism: report of a child with metabolic studies and response to treatment.
Topics: Antimetabolites, Antineoplastic; Antiparkinson Agents; Carbidopa; Child; Cytarabine; Humans; Levodopa; Male; Parkinson Disease, Secondary | 2003 |
The L-dopa response in vascular parkinsonism.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Basal Ganglia Cerebrovascular Disease; Cell Death; Cerebral Infarction; Corpus Striatum; Dominance, Cerebral; Female; Humans; Levodopa; Male; Microcirculation; Neural Pathways; Neurologic Examination; Parkinson Disease, Secondary; Prospective Studies; Substantia Nigra; Treatment Outcome | 2004 |
Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA.
Topics: Animals; Apomorphine; Autoradiography; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Receptor, Adenosine A2A; RNA, Messenger; Stereotyped Behavior; Sympathectomy, Chemical; Sympatholytics; Up-Regulation | 2004 |
Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cell Count; Dyskinesias; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2004 |
NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
Topics: Animals; Excitatory Amino Acid Antagonists; Functional Laterality; Levodopa; Locomotion; Male; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Rotation; Serine; Stereotyped Behavior; Sympathectomy, Chemical | 2004 |
Basal ganglia hyperperfusion in a patient with systemic lupus erythematosus-related parkinsonism.
Topics: Adult; Antiparkinson Agents; Basal Ganglia; Delirium; Epilepsy, Tonic-Clonic; Female; Hallucinations; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Levodopa; Lupus Erythematosus, Systemic; Parkinson Disease, Secondary; Prednisolone; Tomography, Emission-Computed, Single-Photon | 2004 |
Effect of levodopa treatment for parkinsonism in welders: a double-blind study.
Topics: Age of Onset; Brain; Clinical Trials as Topic; Diagnosis, Differential; Diagnostic Errors; Dopamine Agents; Double-Blind Method; Dystonia; Gait Disorders, Neurologic; Humans; Levodopa; Manganese; Manganese Poisoning; Occupational Exposure; Parkinson Disease, Secondary; Tremor; Welding | 2004 |
Levodopa-responsive posttraumatic parkinsonism is not associated with changes of echogenicity of the substantia nigra.
Topics: Antiparkinson Agents; Brain Injuries; Female; Humans; Iodine Radioisotopes; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease, Secondary; Substantia Nigra; Tomography, Emission-Computed, Single-Photon; Tropanes | 2005 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Immunohistochemistry; Levodopa; Male; Methylphenidate; Motor Activity; Movement; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Behavior, Animal; Brain; Brain Chemistry; Cell Membrane; Corpus Striatum; Discs Large Homolog 1 Protein; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesias; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Membrane Proteins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Subcellular Fractions; Synapses | 2005 |
Vascular parkinsonism--an important update.
Topics: Antiparkinson Agents; Diagnosis, Differential; Diagnostic Imaging; Humans; Intracranial Arteriosclerosis; Levodopa; Neurologic Examination; Neuropsychological Tests; Olfaction Disorders; Parkinson Disease; Parkinson Disease, Secondary; Sensitivity and Specificity | 2005 |
Different clinical and evolutional patterns in late idiopathic and vascular parkinsonism.
Topics: Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary; Parkinsonian Disorders; Prognosis; Treatment Outcome | 2005 |
[A case of interval form of carbon monoxide poisoning with a remarkable recovery].
Topics: Acute Disease; Aged; Antiparkinson Agents; Brain; Carbon Monoxide Poisoning; Cytidine Diphosphate Choline; Drug Therapy, Combination; Female; Humans; Hyperbaric Oxygenation; Levodopa; Parkinson Disease, Secondary; Selegiline | 2005 |
Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Corpus Striatum; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Hydroxyindoleacetic Acid; Levodopa; Male; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Serotonin | 2005 |
Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.
Topics: alpha-Methyltyrosine; Amphetamines; Animals; Antiparkinson Agents; Basal Ganglia; Blepharoptosis; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Female; Levodopa; Male; Mice; Motor Activity; Nomifensine; Norepinephrine; Parkinson Disease, Secondary; Phenotype; Piperazines; Tyrosine 3-Monooxygenase | 2005 |
Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Cell Line; Corpus Striatum; Dependovirus; Dimerization; Disease Models, Animal; Dopamine; Gene Dosage; Gene Expression Regulation; Genetic Therapy; Genetic Vectors; Humans; Levodopa; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Recombination, Genetic; Sirolimus; Stereotyped Behavior; Transduction, Genetic | 2006 |
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Benzodiazepines; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Haplorhini; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Rotarod Performance Test; Time Factors | 2005 |
Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dopamine; Fungicides, Industrial; Herbicides; Immunohistochemistry; Levodopa; Male; Maneb; Mice; Mice, Inbred C57BL; Motor Activity; Neostriatum; Nerve Degeneration; Neuroprotective Agents; Paraquat; Parkinson Disease, Secondary; Phytotherapy; Plant Roots; Polygonum; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Caffeine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Levodopa; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease, Secondary; Random Allocation; Time Factors | 2006 |
Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Corpus Striatum; Dependovirus; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gene Transfer Techniques; Immunohistochemistry; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; MPTP Poisoning; Neurons; Parkinson Disease, Secondary; Positron-Emission Tomography; Time Factors | 2006 |
Pallido-pyramidal syndrome with blepharospasm and good response to levodopa.
Topics: Adult; Antiparkinson Agents; Blepharospasm; Female; Globus Pallidus; Humans; Levodopa; Parkinson Disease, Secondary; Pyramidal Tracts; Syndrome | 2005 |
Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Protein Subunits; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Synapses; Transfection | 2006 |
L-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases.
Topics: Animals; Antiparkinson Agents; Dopamine; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Protein Kinase C; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; src-Family Kinases; Time Factors | 2006 |
A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hospitals, University; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Patient Admission; Retrospective Studies; Risk Factors; Turkey | 2006 |
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzoxazoles; Denervation; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Image Processing, Computer-Assisted; In Situ Hybridization; Levodopa; Macaca fascicularis; Motor Activity; Neuroprotective Agents; Oligonucleotide Probes; Ovariectomy; Parkinson Disease, Secondary; Piperidines; Pyrimidines; Receptor, Adenosine A2A; Receptors, N-Methyl-D-Aspartate; Triazoles | 2006 |
Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Laughter; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Piperazines; Psychoses, Substance-Induced; Quetiapine Fumarate; Thiazoles | 2007 |
Reversible Parkinsonism and T1W pallidal hyperintensities in acute liver failure.
Topics: Adult; Antiparkinson Agents; Female; Globus Pallidus; Humans; Levodopa; Liver Failure, Acute; Magnetic Resonance Imaging; Parkinson Disease, Secondary; Parkinsonian Disorders | 2006 |
Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzylamines; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Enzyme Inhibitors; Female; Immunohistochemistry; Levodopa; Neostriatum; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Stereotyped Behavior; Subcellular Fractions; Sulfonamides; Sympatholytics | 2006 |
Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; Levodopa; Macaca fascicularis; Movement Disorders; Nerve Tissue Proteins; Parkinson Disease, Secondary; Proteome | 2006 |
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Male; Models, Biological; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Protein Kinase C; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors | 2007 |
Vascular parkinsonism: analysis of seven cases.
Topics: Aged; Antiparkinson Agents; Brain; Diagnosis, Differential; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary | 2006 |
Two cases of rapid onset Parkinson's syndrome following toxic ingestion of ethylene glycol and methanol.
Topics: Acute Disease; Adult; Aged; Antiparkinson Agents; Basal Ganglia; Carbidopa; Ethylene Glycol; Female; Humans; Levodopa; Male; Methanol; Necrosis; Parkinson Disease, Secondary; Respiratory Insufficiency; Tomography, X-Ray Computed | 2007 |
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dynorphins; Enkephalins; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tacrine; Tremor; Triazoles | 2007 |
[123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Corpus Striatum; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Statistics, Nonparametric; Tomography, Emission-Computed, Single-Photon; Tropanes | 2007 |
[Effects of tetramethylpyrazine on brain oxidative damage induced by intracerebral perfusion of L-DOPA in rats with Parkinson's disease].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Catechols; Chromatography, High Pressure Liquid; Corpus Striatum; Hydroxybenzoates; Levodopa; Male; Microdialysis; Oxidative Stress; Oxidopamine; Parkinson Disease, Secondary; Pyrazines; Random Allocation; Rats; Rats, Sprague-Dawley | 2007 |
Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Benzylamines; Brain; Caffeine; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Male; Motor Activity; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2007 |
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Basal Ganglia; Benzamides; Benzoxazines; Cannabinoids; Capsaicin; Carbamates; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Endocannabinoids; Levodopa; Male; Morpholines; Naphthalenes; Oxidopamine; Parkinson Disease, Secondary; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; TRPV Cation Channels | 2007 |
Protective effects of metallothionein against dopamine quinone-induced dopaminergic neurotoxicity.
Topics: Animals; Cell Line; Cytoprotection; Dopamine; Dopamine Agents; Levodopa; Metallothionein; Mice; Mice, Knockout; Oxidopamine; Parkinson Disease, Secondary; RNA, Messenger; Zinc | 2007 |
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nervous System Stimulants; Citalopram; Dopamine Agents; Drinking; Dyskinesia, Drug-Induced; Image Processing, Computer-Assisted; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Selective Serotonin Reuptake Inhibitors; Serotonin; Stereotyped Behavior; Sympatholytics; Synaptic Transmission | 2008 |
Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism.
Topics: Animals; Autoradiography; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Oxidopamine; Parkinson Disease, Secondary; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; RNA, Messenger; Serotonin Receptor Agonists | 2008 |
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease.
Topics: Animals; Dyskinesias; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Lovastatin; Male; Parkinson Disease, Secondary; Rats; Rats, Wistar; Severity of Illness Index | 2008 |
Diagnostic problems in Parkinson's disease.
Topics: Diagnosis, Differential; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Psychomotor Performance | 1984 |
Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Carbidopa; Drug Combinations; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease; Parkinson Disease, Secondary | 1983 |
Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
Topics: Aged; Antipsychotic Agents; Carbidopa; Corpus Striatum; Depressive Disorder; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Metoclopramide; Parkinson Disease, Secondary; Receptors, Dopamine | 1984 |
Parkinson's disease, 1984.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Pyridines | 1984 |
Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
Topics: Age Factors; Animals; Antipsychotic Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior, Animal; Brain Chemistry; Dopamine; Dopamine beta-Hydroxylase; Dose-Response Relationship, Drug; Female; Humans; Hydroxydopamines; Lesch-Nyhan Syndrome; Levodopa; Motor Activity; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Receptors, Dopamine; Serotonin | 1984 |
Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline).
Topics: Drug Therapy, Combination; Humans; Levodopa; Outcome and Process Assessment, Health Care; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Selegiline; Time Factors | 1983 |
"On-off" phenomenon in Parkinson's disease: correlation to the concentration of dopa in plasma.
Topics: Aged; Amino Acids; Blood-Brain Barrier; Brain; Dihydroxyphenylalanine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Receptors, Dopamine | 1984 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Callitrichinae; Caudate Nucleus; Dopamine; Female; Homovanillic Acid; Levodopa; Parkinson Disease, Secondary; Putamen; Pyridines | 1984 |
Observations made with L-deprenil (Jumex) in the long-term treatment of outpatients with Parkinson's syndrome.
Topics: Aged; Ambulatory Care; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Phenethylamines; Selegiline; Statistics as Topic; Time Factors | 1983 |
[Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
Topics: Administration, Oral; Adult; Aged; Combined Modality Therapy; Electrophoresis; Female; Humans; Intracranial Arteriosclerosis; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary | 1984 |
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Carbidopa; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Parkinson Disease, Secondary; Pyridines | 1984 |
Cerebral blood flow in Parkinson's syndrome.
Topics: Aged; Cerebrovascular Circulation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Xenon Radioisotopes | 1984 |
[Parkinson syndrome, frontal tumor and L-dopa].
Topics: Adult; Astrocytoma; Brain Neoplasms; Frontal Lobe; Humans; Levodopa; Male; Parkinson Disease, Secondary | 1984 |
[Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1984 |
Dissociation of thyrotropin and prolactin responsiveness to thyrotropin releasing hormone stimulation in L-dopa treated parkinsonian patients.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone | 1981 |
Clinicopharmacological study of long-term Jumex + Dopaflex combination treatment in Parkinson's syndrome.
Topics: Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Phenethylamines; Selegiline; Time Factors | 1982 |
Hip fractures in patients with Parkinson's syndrome.
Topics: Aged; Bronchopneumonia; Female; Fracture Fixation, Internal; Hip Fractures; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary | 1983 |
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
Topics: Adult; Aged; alpha-Methyltyrosine; Carbidopa; Dopamine; Dopamine Antagonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyltyrosines; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Reserpine; Synapses; Tetrabenazine | 1983 |
Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism.
Topics: Cerebrospinal Fluid Shunts; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydrocephalus; Levodopa; Male; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; von Willebrand Diseases | 1982 |
[New aspects of chronic occupational manganese poisoning].
Topics: Amantadine; Diagnosis, Differential; Humans; Levodopa; Manganese Poisoning; Occupational Diseases; Parkinson Disease, Secondary | 1982 |
[Improper treatment of patients with parkinsonism due to drug use].
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Psychotropic Drugs | 1982 |
[Generating mechanism and treatment of parkinsonian symptoms].
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary | 1982 |
A perplexing case of juvenile extrapyramidal disease.
Topics: Adolescent; Atrophy; Basal Ganglia Diseases; Bromocriptine; Electroencephalography; Female; Globus Pallidus; Humans; Levodopa; Parkinson Disease, Secondary; Tomography, X-Ray Computed | 1981 |
Electroretinogram in parkinsonism and effects of L-DOPA.
Topics: Electroretinography; Humans; Levodopa; Parkinson Disease, Secondary | 1981 |
[Crises in the course of Parkinson's disease].
Topics: Aged; Amantadine; Bromocriptine; Depression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Psychotic Disorders | 1980 |
[Current treatment of Parkinsonian syndrome].
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease, Secondary | 1980 |
Increased incidence of levodopa therapy following metoclopramide use.
Topics: Aged; Case-Control Studies; Female; Humans; Levodopa; Male; Metoclopramide; Parkinson Disease, Secondary | 1995 |
L-dopa resistant parkinsonism in an adult woman with a cyst in the posterior fossa.
Topics: Adult; Brain Diseases; Brain Stem; Cranial Fossa, Posterior; Cysts; Dandy-Walker Syndrome; Diagnosis, Differential; Female; Humans; Levodopa; Magnetic Resonance Imaging; Neurologic Examination; Parkinson Disease, Secondary | 1993 |
Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Behavior, Animal; Dextromethorphan; Dopamine Agonists; Drug Interactions; Levodopa; Locomotion; Male; Mice; Mice, Inbred Strains; Motor Activity; Parkinson Disease, Secondary; Phenethylamines; Receptors, Dopamine D1; Receptors, Dopamine D2; Reserpine | 1995 |
Parkinsonism and bipolar affective disorder.
Topics: Aged; Antiparkinson Agents; Bipolar Disorder; Carbidopa; Clonazepam; Dopamine; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium Carbonate; Male; Parkinson Disease, Secondary | 1995 |
L-DOPA metabolism in cortical and striatal tissues in an animal model of parkinsonism.
Topics: Animals; Dopamine; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Stereotaxic Techniques; Tyrosine | 1995 |
The levodopa test in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Geriatric Assessment; Humans; Levodopa; Male; Motor Skills; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Reaction Time; Walking | 1995 |
"Pure" striatonigral degeneration and Parkinson's disease: a comparative clinical study.
Topics: Aged; Corpus Striatum; Diagnosis, Differential; Disability Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Nerve Degeneration; Neurologic Examination; Olivopontocerebellar Atrophies; Parkinson Disease; Parkinson Disease, Secondary; Substantia Nigra | 1995 |
Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Autoradiography; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Imidazoles; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, GABA | 1995 |
Functional studies on monoaminergic transmitter release in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; Animals; Apomorphine; Biogenic Monoamines; Dopamine; Dopamine Agents; Dopamine Antagonists; Hydroxyindoleacetic Acid; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Rats; Rats, Wistar; Stereotyped Behavior; Tryptophan | 1993 |
Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey.
Topics: Afferent Pathways; Animals; Apomorphine; Axonal Transport; Brain Mapping; Chorea; Dyskinesia, Drug-Induced; Dystonia; Globus Pallidus; Horseradish Peroxidase; Levodopa; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary; Stereotaxic Techniques; Thalamus; Wheat Germ Agglutinins | 1993 |
NMDA receptor blockade reverses motor response alterations induced by levodopa.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dizocilpine Maleate; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Rotation; Stereotyped Behavior | 1994 |
[Apomorphine as adjuvant treatment in idiopathic Parkinson syndrome].
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary | 1994 |
NMDA antagonist effects on the development of L-dopa behavioral sensitization in rats.
Topics: Animals; Dizocilpine Maleate; Dominance, Cerebral; Dopamine; Dose-Response Relationship, Drug; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Stereotyped Behavior; Substance Withdrawal Syndrome; Synaptic Transmission; Tegmentum Mesencephali | 1995 |
Levodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders.
Topics: Adult; Aged; Carbidopa; Cerebrovascular Circulation; Drug Therapy, Combination; Female; Humans; Intracranial Arteriosclerosis; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Olivopontocerebellar Atrophies; Parkinson Disease; Parkinson Disease, Secondary; Supranuclear Palsy, Progressive; Tomography, X-Ray Computed; Treatment Outcome; Xenon | 1995 |
Amiodarone-induced parkinsonism: a case report and pathogenetic discussion.
Topics: Amiodarone; Arrhythmias, Cardiac; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary | 1995 |
MRI and PET studies of manganese-intoxicated monkeys.
Topics: Animals; Carbidopa; Corpus Striatum; Deoxyglucose; Drug Therapy, Combination; Dystonia; Fluorodeoxyglucose F18; Globus Pallidus; Glucose; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Male; Manganese Poisoning; Parkinson Disease, Secondary; Raclopride; Salicylamides; Substantia Nigra; Tomography, Emission-Computed | 1995 |
Adrenal medulla and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Carbidopa; Catecholamines; Disease Models, Animal; Drug Combinations; Humans; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary | 1994 |
Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Azepines; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Injections, Intraperitoneal; Injections, Intravenous; Injections, Subcutaneous; Levodopa; Male; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary | 1994 |
Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration.
Topics: Amphetamine; Animals; Apomorphine; Denervation; Immunohistochemistry; Levodopa; Male; Medial Forebrain Bundle; Movement; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Tyrosine 3-Monooxygenase | 1994 |
Dopa-responsive dystonia simulating cerebral palsy.
Topics: Adolescent; Adult; Biopterins; Carbidopa; Cerebral Palsy; Child; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Dystonia; Female; Follow-Up Studies; Homovanillic Acid; Humans; Levodopa; Male; Neopterin; Neurologic Examination; Parkinson Disease, Secondary | 1994 |
Levodopa in pregnancy.
Topics: Adult; Carbidopa; Female; Humans; Levodopa; Lymphoma, Non-Hodgkin; Parkinson Disease, Secondary; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 1995 |
Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat.
Topics: Amphetamine; Animals; Apomorphine; Body Weight; Immunohistochemistry; Levodopa; Male; Motor Activity; Nerve Fibers; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Substantia Nigra; Tyrosine 3-Monooxygenase | 1994 |
Portable device for quantifying parkinsonian wrist rigidity.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Muscle Tonus; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Psychotic Disorders; Risk Factors; Transducers | 1994 |
Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; G(M1) Ganglioside; Levodopa; Macaca fascicularis; Neurons; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 1994 |
Effects of drug manipulations on anterior components of somatosensory evoked potentials in a parkinsonian animal model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cholinergic Antagonists; Electric Stimulation; Electrophysiology; Evoked Potentials, Somatosensory; gamma-Aminobutyric Acid; Levodopa; Macaca fascicularis; Median Nerve; Norepinephrine; Parkinson Disease, Secondary; Receptors, N-Methyl-D-Aspartate | 1994 |
A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization.
Topics: Amphetamine; Animals; Brain; Carbidopa; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Combinations; Functional Laterality; Immunohistochemistry; Levodopa; Male; Mesencephalon; Models, Neurological; Motor Activity; Nucleus Accumbens; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Tyrosine 3-Monooxygenase | 1994 |
Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Biotransformation; Corpus Striatum; Denervation; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Homovanillic Acid; Levodopa; Male; Microdialysis; Nomifensine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Tetrodotoxin | 1994 |
Excitotoxic lateral pallidotomy does not relieve L-dopa-induced dyskinesia in MPTP parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary | 1994 |
Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amino Acids; Animals; Blood-Brain Barrier; Female; Levodopa; Macaca fascicularis; Macaca mulatta; Male; Parkinson Disease, Secondary | 1994 |
L-dopa induced increases in brain uric acid in an animal model of Parkinson's disease: a relationship to behavioral activation.
Topics: Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympathectomy, Chemical; Uric Acid; Ventral Tegmental Area | 1994 |
Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Carbidopa; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinson Disease, Secondary; Psychomotor Performance; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1993 |
Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues.
Topics: Animals; Biopterins; Caudate Nucleus; Dopamine; Female; Isoquinolines; Levodopa; Male; Neurons; Parkinson Disease, Secondary; Putamen; Saimiri; Structure-Activity Relationship; Substantia Nigra; Tetrahydroisoquinolines; Tyrosine 3-Monooxygenase | 1993 |
Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
Topics: Animals; Apomorphine; Autoradiography; Benzazepines; Brain Chemistry; Caudate Nucleus; Dopamine Agents; Female; Infusions, Intravenous; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary; Putamen; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulpiride | 1993 |
Long-term correction of rat model of Parkinson's disease by gene therapy.
Topics: Animals; Animals, Newborn; Apomorphine; Brain; Cells, Cultured; Dopamine; Drug Carriers; Female; Genetic Therapy; Levodopa; Motor Activity; Muscles; Oxidopamine; Parkinson Disease, Secondary; Phosphatidylethanolamines; Plasmids; Rats; Rats, Sprague-Dawley; Time Factors; Transplantation, Heterotopic; Tyrosine 3-Monooxygenase | 1993 |
[Long-latency auditory evoked responses in Parkinson disease and in parkinsonism induced by neuroleptics].
Topics: Aged; Antipsychotic Agents; Evoked Potentials, Auditory; Female; Humans; Levodopa; Male; Parkinson Disease; Parkinson Disease, Secondary; Reaction Time | 1993 |
Rotations induced by L-dopa in parkinsonian rats are reduced by an ingestion of amino acids.
Topics: Amino Acids; Animals; Levodopa; Male; Neostriatum; Neural Pathways; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotation; Stereotyped Behavior; Substantia Nigra | 1993 |
Meperidine and reversible parkinsonism.
Topics: Adult; Benserazide; Drug Therapy, Combination; Humans; Levodopa; Male; Meperidine; Neurologic Examination; Parkinson Disease, Secondary; Substance Withdrawal Syndrome | 1994 |
Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
Topics: Activities of Daily Living; Adult; Aged; Chorea; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine D1; Video Recording | 1994 |
Apomorphine increases blood glucose concentrations in Parkinson's disease.
Topics: Aged; Apomorphine; Blood Glucose; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1994 |
Hemiparkinsonism-hemiatrophy syndrome: neuroradiological and neurophysiological findings.
Topics: Adult; Cerebral Infarction; Evoked Potentials, Somatosensory; Functional Laterality; Humans; Levodopa; Magnetic Resonance Imaging; Male; Mesencephalon; Muscular Atrophy; Neurologic Examination; Parkinson Disease, Secondary; Reaction Time; Syndrome | 1994 |
Parkinsonism induced by solvent abuse.
Topics: Administration, Inhalation; Adult; Brain; Female; Humans; Levodopa; Parkinson Disease, Secondary; Solvents; Substance-Related Disorders; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1994 |
Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism.
Topics: Adult; Aged; Biperiden; Brain; Electric Stimulation; Evoked Potentials; Female; Humans; Levodopa; Magnetics; Male; Middle Aged; Motor Cortex; Muscles; Parkinson Disease; Parkinson Disease, Secondary; Peripheral Nerves | 1994 |
Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetamides; Analysis of Variance; Animals; Anticonvulsants; Antiparkinson Agents; Brain; Carbidopa; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors | 1994 |
Modulatory effects of testosterone on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Drug Implants; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; MPTP Poisoning; Neurotoxins; Orchiectomy; Parkinson Disease, Secondary; Reference Values; Species Specificity; Testosterone | 1994 |
Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzazepines; Brain; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Spiperone | 1993 |
A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Callithrix; Dialysis; Drug Interactions; Female; Levodopa; Locomotion; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Picolinic Acids | 1993 |
[Parkinsonian features of Steele-Richardson-Olszewski syndrome].
Topics: Aged; Atrophy; Brain Stem; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Supranuclear Palsy, Progressive; Tomography, X-Ray Computed | 1993 |
Progression after chronic manganese exposure.
Topics: Adult; Chronic Disease; Follow-Up Studies; Humans; Levodopa; Male; Manganese; Middle Aged; Movement Disorders; Nervous System Diseases; Occupational Exposure; Parkinson Disease, Secondary | 1993 |
Parkinson's disease.
Topics: Aged; Diagnosis, Differential; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1993 |
Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.
Topics: Carbidopa; Female; Follow-Up Studies; Humans; Levodopa; Male; Minnesota; Parkinson Disease; Parkinson Disease, Secondary; Survival Analysis; Survival Rate; Time Factors | 1993 |
CSF biopterin levels and clinical features of patients with juvenile parkinsonism.
Topics: Adult; Biopterins; Dose-Response Relationship, Drug; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Neopterin; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Risk Factors; Thalamic Nuclei | 1993 |
Clinical heterogeneity of dopa-responsive dystonia: PET observations.
Topics: Adult; Aged; Corpus Striatum; Diagnosis, Differential; Dihydroxyphenylalanine; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Tomography, Emission-Computed | 1993 |
PET scan study on the dopaminergic system in a Japanese patient with hereditary progressive dystonia (Segawa's disease). Case report.
Topics: Corpus Striatum; Dihydroxyphenylalanine; Dystonia; Female; Humans; Japan; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Tomography, Emission-Computed | 1993 |
The clinical features of Parkinson's disease in 100 histologically proven cases.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Corpus Striatum; Dementia; Female; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Neurofibrillary Tangles; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Tissue Donors | 1993 |
Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
Topics: Benserazide; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Humans; Levodopa; Motor Activity; Movement Disorders; Neurologic Examination; Ocular Motility Disorders; Parkinson Disease; Parkinson Disease, Secondary; Supranuclear Palsy, Progressive | 1993 |
Fifteen months' follow-up on bilateral embryonic mesencephalic grafts in two cases of severe MPTP-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Activities of Daily Living; Adult; Brain Tissue Transplantation; Dominance, Cerebral; Female; Fetal Tissue Transplantation; Follow-Up Studies; Gait; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary | 1993 |
Developing a stable bilateral model of parkinsonism in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Carotid Arteries; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Feeding Behavior; Female; Injections, Intra-Arterial; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease, Secondary | 1993 |
Extrapyramidal syndrome responsive to dopaminergic treatment following recovery from central pontine myelinolysis.
Topics: Basal Ganglia Diseases; Biperiden; Carbidopa; Chlorthalidone; Coma; Drug Therapy, Combination; Female; Humans; Hypertension; Hyponatremia; Levodopa; Lisuride; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Pons; Quadriplegia; Saline Solution, Hypertonic; Tomography, X-Ray Computed | 1993 |
Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
Topics: Animals; Brain; Corpus Striatum; Levodopa; Male; Motor Activity; Neurons; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Substantia Nigra | 1993 |
[Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease].
Topics: Aged; Apomorphine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary | 1993 |
Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum.
Topics: Animals; Antiparkinson Agents; Caudate Nucleus; Dopamine Agents; Enkephalins; Gene Expression; In Situ Hybridization; Levodopa; Macaca fascicularis; MPTP Poisoning; Neostriatum; Oligonucleotides, Antisense; Parkinson Disease, Secondary; Protein Precursors; Putamen; RNA, Messenger; Tachykinins | 1995 |
L-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats.
Topics: Acetylcholine; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Synergism; Ergolines; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes | 1995 |
Esters of L-dopa: structure-hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonism.
Topics: Animals; Behavior, Animal; Chemical Phenomena; Chemistry, Physical; Disease Models, Animal; Esters; Humans; Hydrolysis; Levodopa; Male; Parkinson Disease, Secondary; Prodrugs; Rats; Rats, Wistar; Solubility; Structure-Activity Relationship | 1995 |
Levodopoa but not bromocriptine induces AP-1 and creb DNA-binding activity in the dopamine-depleted striatum of the rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Base Sequence; Behavior, Animal; Bromocriptine; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine; Dopamine Agonists; Levodopa; Male; Molecular Sequence Data; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Transcription Factor AP-1 | 1996 |
Cytosine arabinoside and amphotericin B-induced parkinsonism.
Topics: Amphotericin B; Carbidopa; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myelomonocytic, Acute; Levodopa; Lung Diseases; Middle Aged; Parkinson Disease, Secondary | 1996 |
Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study.
Topics: Animals; Basal Ganglia; Brain; Carbidopa; Chlorides; Gliosis; Globus Pallidus; Levodopa; Macaca mulatta; Male; Manganese Compounds; Manganese Poisoning; Parkinson Disease, Secondary; Poisoning; Substantia Nigra | 1996 |
Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Chorea; Dyskinesia, Drug-Induced; Dystonia; Excitatory Amino Acid Antagonists; Female; Isoquinolines; Levodopa; Macaca fascicularis; Macaca mulatta; Male; Parkinson Disease, Secondary; Receptors, N-Methyl-D-Aspartate | 1996 |
Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study.
Topics: Aged; Aged, 80 and over; Animals; Basal Ganglia; Densitometry; Electron Transport Complex IV; Female; Histocytochemistry; Humans; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease; Parkinson Disease, Secondary | 1996 |
Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Female; Globus Pallidus; Glutamate Decarboxylase; Humans; In Situ Hybridization; Levodopa; Macaca fascicularis; Male; Parkinson Disease, Secondary; RNA, Messenger; Substantia Nigra | 1996 |
Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Brain; Carbidopa; Drug Therapy, Combination; Female; Handwriting; Humans; Levodopa; Male; Microcomputers; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Signal Processing, Computer-Assisted; Treatment Outcome | 1996 |
Parkinsonian manifestations in a patient with homocystinuria.
Topics: Antiparkinson Agents; Basal Ganglia Diseases; Child; Homocystinuria; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary | 1996 |
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Neurologic Examination; Parkinson Disease, Secondary | 1995 |
Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Brain; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Receptors, Dopamine D1 | 1996 |
Dopaminergic transplants alter in vivo activity of tryptophan hydroxylase in the striatum in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Brain Tissue Transplantation; Disease Models, Animal; Dopamine; Female; Fetal Tissue Transplantation; Levodopa; Mesencephalon; Microdialysis; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Tryptophan Hydroxylase | 1996 |
[Parkinson syndrome after CO poisoning. Unexpected late manifestation and favorable prognosis].
Topics: Carbon Monoxide; Carbon Monoxide Poisoning; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Suicide, Attempted; Tomography, X-Ray Computed | 1996 |
Drug-induced parkinsonism after allogeneic bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Female; Haloperidol; Humans; Levodopa; Parkinson Disease, Secondary; Transplantation, Homologous | 1996 |
Antiparkinsonian effect of flupirtine in monoamine-depleted rats.
Topics: Aminopyridines; Analgesics; Animals; Antiparkinson Agents; Biogenic Monoamines; Drug Synergism; Electromyography; Levodopa; Male; Neuroprotective Agents; Parkinson Disease, Secondary; Rats; Rats, Wistar | 1996 |
Brainstem myoclonus in a patient with non-dopa-responsive parkinsonism.
Topics: Brain Stem; Electroencephalography; Electromyography; Evoked Potentials, Somatosensory; Humans; Levodopa; Male; Middle Aged; Myoclonus; Parkinson Disease, Secondary; Reflex, Startle; Reticular Formation; Treatment Failure | 1996 |
Dopaminergic transplants suppress L-DOPA-induced Fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Caudate Nucleus; Corpus Striatum; Dizocilpine Maleate; Dopamine; Female; Fetal Tissue Transplantation; Levodopa; Mesencephalon; Methamphetamine; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 1996 |
Mapping drug-induced changes in cerebral R2* by Multiple Gradient Recalled Echo functional MRI.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Carbidopa; Female; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Parkinson Disease, Secondary | 1996 |
Postencephalitic stereotyped involuntary movements responsive to L-Dopa.
Topics: Adult; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Encephalitis; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary; Putamen; Receptors, Dopamine D2; Stereotyped Behavior; Tomography, X-Ray Computed; Trihexyphenidyl | 1996 |
Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dominance, Cerebral; Electric Stimulation Therapy; Electromyography; Levodopa; Macaca mulatta; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Thalamic Nuclei | 1996 |
Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys.
Topics: Animals; Cell Count; Cell Size; Corpus Striatum; Dopamine Agents; Levodopa; Macaca fascicularis; MPTP Poisoning; Neurons; Parkinson Disease, Secondary; Receptors, Dopamine D2; RNA, Messenger | 1996 |
Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benserazide; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Injections; Injections, Intraventricular; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Rotation; Stereotyped Behavior; Substantia Nigra | 1995 |
Sodium benzoate differentially blocks circling induced by D-and L-dopa in the hemi-parkinsonian rat.
Topics: Amino Acid Oxidoreductases; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Benzoates; Benzoic Acid; Carbidopa; Female; Food Preservatives; Levodopa; Locomotion; Parkinson Disease, Secondary; Phenylpyruvic Acids; Rats; Rats, Sprague-Dawley | 1996 |
Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA.
Topics: Aged; Aged, 80 and over; Animals; Basal Ganglia; Corpus Striatum; Denervation; Electron Transport Complex IV; Enzyme Induction; Female; Globus Pallidus; Humans; In Situ Hybridization; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Nerve Tissue Proteins; Parkinson Disease; Parkinson Disease, Secondary; RNA, Messenger; Substantia Nigra | 1997 |
Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Hyperkinesis; Levodopa; Macaca fascicularis; Movement; Parkinson Disease, Secondary | 1996 |
Whooping cough and Parkinson's disease. The Europarkinson Preparatory Activity Research Group.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Child; Child, Preschool; Cohort Studies; Humans; Iceland; Incidence; Infant; Infant, Newborn; Levodopa; Middle Aged; Parkinson Disease, Secondary; Prevalence; Risk Factors; Whooping Cough | 1996 |
The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Brain Mapping; Caudate Nucleus; Corpus Striatum; Dopamine; Female; Levodopa; Macaca fascicularis; Male; Parkinson Disease, Secondary; Putamen; Receptors, Dopamine D1 | 1997 |
Hydrocephalic parkinsonism due to Paget's disease of bone: dramatic improvement following ventriculoperitoneal shunt and temporary levodopa/carbidopa therapy.
Topics: Aged; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Hydrocephalus; Levodopa; Neurologic Examination; Osteitis Deformans; Parkinson Disease, Secondary; Ventriculoperitoneal Shunt | 1997 |
A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease.
Topics: Animals; Apomorphine; Functional Laterality; Hippocampus; Infusions, Parenteral; Levodopa; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Rotation | 1997 |
Validation of a rodent model of Parkinson's Disease: evidence of a therapeutic window for oral Sinemet.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Stereotyped Behavior | 1996 |
Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Cell Transplantation; Disease Models, Animal; Dopamine; Drug Combinations; Drug Synergism; Levodopa; Male; Movement Disorders; Neostriatum; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotation | 1997 |
[The effect of liposomal form of L-Dopa on the development of parkinsonian syndrome in mice].
Topics: Animals; Dopamine Agents; Drug Carriers; Levodopa; Liposomes; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease, Secondary | 1997 |
Nullification of a positive correlation between urinary levels of alpha 1-microglobulin and ulinastatin by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alpha-Globulins; Animals; Antiparkinson Agents; Brain; Glycoproteins; Injections, Intraventricular; Levodopa; Male; Mice; Parkinson Disease, Secondary | 1997 |
(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Carbidopa; Dopamine Antagonists; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Piperidines; Posture; Raclopride; Salicylamides | 1997 |
Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Cerebral Ventricles; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Female; Glial Cell Line-Derived Neurotrophic Factor; Injections, Intraventricular; Levodopa; Macaca mulatta; Motor Activity; Nerve Growth Factors; Nerve Tissue Proteins; Neuroprotective Agents; Parkinson Disease, Secondary; Stereotyped Behavior | 1997 |
Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease, Secondary; Quinolones; Quinpirole; Receptors, Dopamine D1; Thiophenes | 1997 |
High prevalence of Parkinson's disease in the Faroe Islands.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Denmark; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Prevalence; Tremor | 1997 |
[The effect of liposomal form of L-Dopa on the level of dopamine, its metabolites, and phospholipid metabolism in the striatum of mice with experimental parkinsonian syndrome].
Topics: Animals; Blood-Brain Barrier; Corpus Striatum; Dopamine; Dopamine Agents; Levodopa; Liposomes; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Parkinson Disease, Secondary; Phospholipids | 1996 |
[The effect of prolonged parenteral administration of liposomes and L-Dopa incorporated into liposomes on metabolism of dopamine and its metabolites in the striatum of mice with experimental parkinsonian syndrome].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Drug Carriers; Injections, Intraperitoneal; Levodopa; Liposomes; Male; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary | 1997 |
Systemic lupus erythematosus associated with transverse myelitis and parkinsonian symptoms.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Levodopa; Lupus Erythematosus, Systemic; Myelitis; Parkinson Disease, Secondary; Ribonucleosides | 1997 |
Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Benzazepines; Dopamine Agonists; Haplorhini; Levodopa; Motor Activity; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine; Receptors, Dopamine D1 | 1998 |
Use of carbidopa-levodopa in a patient with hydrocephalus and frozen movement.
Topics: Adult; Antiparkinson Agents; Basal Ganglia; Carbidopa; Cerebral Ventricles; Drug Therapy, Combination; Humans; Hydrocephalus; Levodopa; Male; Parkinson Disease, Secondary; Regional Blood Flow; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Ventriculoperitoneal Shunt | 1997 |
A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Count; Chronic Disease; Disease Models, Animal; Disease Progression; Dopamine Agents; Levodopa; Macaca fascicularis; Movement; Neurons; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 1997 |
Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Caudate Nucleus; Dopamine Agonists; Enkephalins; Female; Imidazoles; In Situ Hybridization; Levodopa; Macaca fascicularis; Ovariectomy; Parkinson Disease, Secondary; Protein Precursors; Putamen; Receptors, Dopamine D2; RNA, Messenger; Transcription, Genetic | 1997 |
Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.
Topics: Aged; Antiparkinson Agents; Aspartic Acid; Atrophy; Cerebral Cortex; Choline; Corpus Striatum; Creatinine; Female; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Spectroscopy; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Phosphocreatine; Protons; Putamen; Supranuclear Palsy, Progressive | 1997 |
Parkinsonism associated with acute intracranial hematomas: an [18F]dopa positron-emission tomography study.
Topics: Acute Disease; Adult; Antiparkinson Agents; Brain Neoplasms; Corpus Striatum; Female; Fluorine Radioisotopes; Hematoma; Humans; Levodopa; Parkinson Disease, Secondary; Radiography; Tomography, Emission-Computed | 1997 |
Parkinson's disease: clinical features.
Topics: Aging; Antiparkinson Agents; Diagnosis, Differential; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Treatment Outcome | 1997 |
Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation.
Topics: Animals; Apomorphine; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Dopamine Agonists; Electrochemistry; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra | 1998 |
Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey.
Topics: Animals; Dopamine Agents; Female; Globus Pallidus; Immunohistochemistry; Levodopa; Macaca mulatta; MPTP Poisoning; Neurons; Parkinson Disease, Secondary | 1998 |
Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.
Topics: alpha-Methyltyrosine; Animals; Antiparkinson Agents; Benzeneacetamides; Benzofurans; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reserpine | 1998 |
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Receptors, Dopamine D2 | 1998 |
Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Brain Tissue Transplantation; Carrier Proteins; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; Fetal Tissue Transplantation; Functional Laterality; Haloperidol; Homovanillic Acid; Kinetics; Levodopa; Mazindol; Membrane Glycoproteins; Membrane Transport Proteins; Mesencephalon; Methamphetamine; Microdialysis; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotation; Tritium; Tyrosine 3-Monooxygenase | 1998 |
Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carrier Proteins; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Female; Iodine Radioisotopes; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Fibers; Nerve Tissue Proteins; Neuropeptides; Neurotransmitter Agents; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Radioimmunoassay; Rats; Rats, Wistar; Substantia Nigra; Sulpiride; Sympatholytics; Tyrosine 3-Monooxygenase; Ventral Tegmental Area; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 1998 |
Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Synergism; Electrophysiology; Injections, Intraperitoneal; Levodopa; Male; Membrane Potentials; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Wistar; Selegiline | 1998 |
Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Dependovirus; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Gene Expression Regulation, Enzymologic; Gene Transfer Techniques; GTP Cyclohydrolase; Humans; Levodopa; Male; Microdialysis; Neurons; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Recombinant Proteins; Rotation; Tyrosine 3-Monooxygenase | 1998 |
[Vascular parkinsonism].
Topics: Antiparkinson Agents; Brain Ischemia; Carbidopa; Drug Combinations; Electroencephalography; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease, Secondary; Ultrasonography, Doppler, Transcranial | 1998 |
Dopamine turnover and metabolism in the striatum of parkinsonian rats grafted with genetically-modified human astrocytes.
Topics: Animals; Astrocytes; Cell Line; Corpus Striatum; Dopamine; Genetic Therapy; Humans; Levodopa; Male; Microdialysis; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Transfection; Transgenes; Transplants; Tyrosine 3-Monooxygenase | 1998 |
In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase.
Topics: 3T3 Cells; Animals; Antioxidants; Antiparkinson Agents; Apomorphine; Behavior, Animal; Biopterins; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Fibroblasts; Gene Expression Regulation, Enzymologic; Genetic Therapy; Gliosarcoma; GTP Cyclohydrolase; Humans; Levodopa; Male; Mice; Microdialysis; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Recombinant Fusion Proteins; Retroviridae; Transformation, Genetic; Transgenes; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase | 1998 |
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Clonidine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Levodopa; Lisuride; Locomotion; Male; Mazindol; Methoxydimethyltryptamines; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Rats; Rats, Sprague-Dawley; Sympatholytics; Tritium; Yohimbine | 1998 |
Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Macaca fascicularis; Male; Motor Skills; Neurologic Examination; Nicotinic Agonists; Parkinson Disease, Secondary; Pyridines; Pyrrolidines; Receptors, Cholinergic; Receptors, Nicotinic | 1998 |
MPTP-Induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose.
Topics: Animals; Antiparkinson Agents; Carotid Arteries; Dopamine Agents; Drug Administration Schedule; Female; Follow-Up Studies; Infusions, Intra-Arterial; Levodopa; Macaca nemestrina; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Rotation | 1998 |
Trihexyphenidyl potentiation of L-DOPA: reduced effectiveness three years later in MPTP-induced chronic hemiparkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Chronic Disease; Dopamine Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Female; Levodopa; Macaca nemestrina; MPTP Poisoning; Parkinson Disease, Secondary; Treatment Outcome; Trihexyphenidyl | 1998 |
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Injections, Subcutaneous; Levodopa; Macaca fascicularis; Neurologic Examination; Parkinson Disease, Secondary; Receptors, N-Methyl-D-Aspartate | 1998 |
The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 1998 |
Reevaluation of the striatal role in the expression of turning behavior in the rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Levodopa; Lidocaine; Male; Motor Activity; Organ Specificity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Tyrosine 3-Monooxygenase | 1998 |
Magnetic resonance imaging and 11C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning.
Topics: Basal Ganglia; Bromocriptine; Carbon Monoxide Poisoning; Carbon Radioisotopes; Caudate Nucleus; Cerebral Hemorrhage; Combined Modality Therapy; Convalescence; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Globus Pallidus; Humans; Hyperbaric Oxygenation; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Nerve Tissue Proteins; Parkinson Disease, Secondary; Psychomotor Performance; Putamen; Receptors, Dopamine D2; Spiperone; Tomography, Emission-Computed | 1998 |
Reversible parkinsonism induced by prolonged treatment with valproate.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Remission Induction; Seizures; Valproic Acid | 1998 |
Brain drug delivery system bearing dopamine hydrochloride for effective management of parkinsonism.
Topics: Animals; Antiparkinson Agents; Brain; Catatonia; Dopamine; Drug Delivery Systems; Levodopa; Liposomes; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 1998 |
Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism.
Topics: Aged; Antiparkinson Agents; Blepharospasm; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Recurrence; Sulpiride; Tetrabenazine | 1999 |
MPTP-Induced pallidal lesions in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Chronic Disease; Female; Globus Pallidus; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Parkinson Disease, Secondary | 1999 |
Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models.
Topics: Animals; Biological Transport; Brain; Carrier Proteins; Cocaine; Disease Models, Animal; Dopa Decarboxylase; Dopamine Plasma Membrane Transport Proteins; Female; Gene Expression Regulation; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Neuropeptides; Parkinson Disease, Secondary; Radioligand Assay; Rats; Rats, Wistar; Rotation; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 1999 |
Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antibodies; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Corpus Striatum; Dopamine; Dopamine Agonists; Enzyme Inhibitors; Levodopa; Male; Motor Neurons; Nerve Degeneration; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Phosphoserine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Serine; Sulfonamides; Sympatholytics | 1999 |
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Autoradiography; Behavior, Animal; Bromocriptine; Dopamine Agents; Dopamine Agonists; Dopamine Uptake Inhibitors; Enkephalins; In Situ Hybridization; Levodopa; Lisuride; Male; Mazindol; Medial Forebrain Bundle; Neostriatum; Oligonucleotide Probes; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Radioligand Assay; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1999 |
Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Cerebellum; Corpus Striatum; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Lipid Peroxidation; Male; Mesencephalon; Oxidative Stress; Parkinson Disease, Secondary; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Time Factors | 1998 |
D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Female; Levodopa; Locomotion; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Receptors, Dopamine D1 | 1999 |
Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Dopamine; Dopamine Agents; Female; Fibroblasts; Genetic Therapy; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Neuropeptides; Neurotransmitter Agents; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Transduction, Genetic; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 1999 |
GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist.
Topics: Animals; Antiparkinson Agents; Binding, Competitive; Catalepsy; Cyclopentanes; Drug Evaluation, Preclinical; Drug Synergism; Excitatory Amino Acid Antagonists; Glycine Agents; Haloperidol; Hypnotics and Sedatives; Levodopa; Male; Neuroprotective Agents; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Reserpine | 1999 |
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Synergism; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Microdialysis; Motor Activity; Neostriatum; Neurons; Oxidopamine; Parkinson Disease, Secondary; Pergolide; Rats; Rats, Wistar | 1999 |
Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure.
Topics: Aged; Brain; Cognition Disorders; Humans; Levodopa; Male; Middle Aged; Occupational Exposure; Paint; Parkinson Disease, Secondary; Solvents | 1999 |
Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Receptor, Adenosine A2A | 1999 |
Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinson drugs.
Topics: Adult; Antiparkinson Agents; Brain Edema; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Magnetic Resonance Imaging; Male; Methanol; Parkinson Disease, Secondary; Putamen; Tomography, X-Ray Computed | 1999 |
Central pontine and extrapontine myelinolysis presenting with parkinsonism in a patient with cystic fibrosis.
Topics: Acute Disease; Adult; Antiparkinson Agents; Benserazide; Cystic Fibrosis; Drug Combinations; Humans; Levodopa; Magnetic Resonance Imaging; Male; Myelinolysis, Central Pontine; Parkinson Disease, Secondary; Pons | 1999 |
[Intracerebral transplantation of genetically modified cells for Parkinson's disease].
Topics: 3T3 Cells; Animals; Corpus Striatum; Fetal Tissue Transplantation; Gene Transfer Techniques; Genetic Therapy; Levodopa; Mice; Oxidopamine; Parkinson Disease, Secondary; Rats; Tyrosine 3-Monooxygenase | 1997 |
Principal component analysis of the dynamic response measured by fMRI: a generalized linear systems framework.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Carbidopa; Dopamine Agents; Female; Levodopa; Linear Models; Macaca mulatta; Magnetic Resonance Imaging; Mathematics; Models, Statistical; Parkinson Disease, Secondary; Regression Analysis; Systems Analysis | 1999 |
Glutamate receptor-mediated mechanisms in levodopa-induced motor fluctuations in an experimental model of parkinsonism.
Topics: Animals; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Rotation; Stereotyped Behavior; Time Factors | 1999 |
Nicotine alone and in combination with L-DOPA methyl ester or the D(2) agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agonists; Drug Interactions; Female; Levodopa; Macaca nemestrina; Motor Activity; Nicotine; Parkinson Disease, Secondary; Receptors, Dopamine D2; Rotation; Tetrahydronaphthalenes; Thiophenes | 1999 |
NMSP binding to dopamine and serotonin receptors in MPTP-induced parkinsonism: relation to dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Antiparkinson Agents; Binding Sites; Cerebellum; Dopamine Antagonists; Humans; Levodopa; Male; Models, Chemical; Occupational Diseases; Parkinson Disease, Secondary; Putamen; Receptors, Dopamine; Receptors, Serotonin; Severity of Illness Index; Spiperone; Tomography, Emission-Computed | 1999 |
Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine Agents; Female; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Microdialysis; Parkinson Disease, Secondary; Treatment Outcome | 1999 |
Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Oocytes; Parkinson Disease, Secondary; Rats; Receptors, N-Methyl-D-Aspartate; Valine; Xenopus laevis | 1999 |
Parkinson's disease or Parkinson's diseases?
Topics: Humans; Levodopa; Lewy Bodies; Parkinson Disease; Parkinson Disease, Secondary | 1999 |
Narrow beneficial effect of dextromethorphan on levodopa-induced motor response alterations in an experimental model of parkinsonism.
Topics: Animals; Antiparkinson Agents; Dextromethorphan; Disease Models, Animal; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Treatment Outcome | 1999 |
Migratory basal ganglia lesions in subacute sclerosing panencephalitis (SSPE): clinical implications of axonal spread.
Topics: Adolescent; Axons; Basal Ganglia; Disease Progression; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary; Subacute Sclerosing Panencephalitis; Treatment Failure | 1999 |
Worsening of motor features of parkinsonism with olanzapine.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Olanzapine; Parkinson Disease; Parkinson Disease, Secondary; Pirenzepine; Psychoses, Substance-Induced; Risk Factors | 1999 |
Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys.
Topics: Animals; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine Agents; Fluorine Radioisotopes; Levodopa; Macaca mulatta; Male; Memory; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Psychomotor Performance; Space Perception | 1999 |
Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Membrane; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2000 |
Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Rotation; Substantia Nigra; Sympatholytics | 2000 |
Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Electrophysiology; Female; Globus Pallidus; Levodopa; Macaca mulatta; Neurons; Neuroprotective Agents; Parkinson Disease, Secondary; Riluzole | 2000 |
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Quinpirole; Receptor, Adenosine A2A; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2000 |
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodiazepines; Dioxoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinson Disease, Secondary; Piperidines; Receptors, AMPA; Severity of Illness Index | 2000 |
The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958.
Topics: Animals; Antiparkinson Agents; Arm; Behavior, Animal; Benzazepines; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; Electroencephalography; Epilepsy; Levodopa; Macaca mulatta; Male; Motor Activity; Movement; MPTP Poisoning; Parkinson Disease, Secondary; Predictive Value of Tests; Receptors, Dopamine D1 | 1999 |
Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Haloperidol; Levodopa; Macaca mulatta; Male; Parkinson Disease, Secondary; Piperidines; Rats; Rats, Inbred F344; Reaction Time; Receptors, N-Methyl-D-Aspartate | 2000 |
Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus Striatum; Denervation; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Neurons; Parkinson Disease, Secondary; Receptors, Dopamine; Saimiri; Substantia Nigra | 2000 |
Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus Striatum; Diagnosis, Differential; Disease Models, Animal; Dopamine; Levodopa; Macaca fascicularis; Male; Multiple System Atrophy; Nerve Degeneration; Neurotoxins; Nitro Compounds; Parkinson Disease, Secondary; Propionates; Striatonigral Degeneration | 2000 |
[Follow-up study after enteral manganese poisoning: clinical, laboratory and neuroradiological findings].
Topics: Aged; Aged, 80 and over; Brain; Humans; Levodopa; Magnetic Resonance Imaging; Male; Manganese Poisoning; Parkinson Disease, Secondary; Polyneuropathies; Potassium Permanganate; Psychiatric Status Rating Scales; Remission, Spontaneous | 2000 |
Ineffective subthalamic nucleus stimulation in levodopa-resistant postischemic parkinsonism.
Topics: Antiparkinson Agents; Drug Resistance; Electric Stimulation; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Myocardial Ischemia; Parkinson Disease, Secondary; Subthalamic Nucleus | 2000 |
5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Disease Models, Animal; Dopamine Agonists; Indoles; Levodopa; Locomotion; Male; Oxidopamine; Parkinson Disease, Secondary; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D1; Receptors, Serotonin; Serotonin Antagonists | 2000 |
Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain Tissue Transplantation; Dopamine; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; Hydroxydopamines; Image Processing, Computer-Assisted; In Situ Hybridization; Levodopa; Mesencephalon; Neostriatum; Nerve Endings; Neurons; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Sympathomimetics | 2000 |
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Carbidopa; Catheterization; Caudate Nucleus; Cell Line; Dependovirus; Dopamine; Drug Administration Routes; Drug Combinations; Fluorine Radioisotopes; Genetic Therapy; Genetic Vectors; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Neurons; Parkinson Disease, Secondary; Prodrugs; Putamen; Tomography, Emission-Computed; Tyrosine; Tyrosine 3-Monooxygenase | 2000 |
Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzazepines; Binding, Competitive; Corpus Striatum; Denervation; Dizocilpine Maleate; Dopamine Agonists; Dopamine Antagonists; Enkephalins; Excitatory Amino Acid Antagonists; Gene Expression; Levodopa; Male; Neural Pathways; Neurons; Opioid Peptides; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Sympatholytics; Tachykinins; Tetrahydronaphthalenes; Tritium; Ventral Tegmental Area | 2000 |
The expression of the calcium binding protein calretinin in the rat striatum: effects of dopamine depletion and L-DOPA treatment.
Topics: Animals; Calbindin 2; Calcium-Binding Proteins; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Immunohistochemistry; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Microinjections; Neuropil; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; S100 Calcium Binding Protein G; Tyrosine 3-Monooxygenase | 2000 |
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dopamine Agents; Excitatory Amino Acid Antagonists; Levodopa; Motor Activity; Parkinson Disease; Parkinson Disease, Secondary; Piperidines | 2000 |
Autoradiographic analysis of N-methyl-D-aspartate receptor binding in monkey brain: effects of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine and levodopa treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain Chemistry; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Excitatory Amino Acid Antagonists; Iodine Radioisotopes; Levodopa; Parkinson Disease, Secondary; Radioligand Assay; Receptors, N-Methyl-D-Aspartate; Saimiri | 2000 |
Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Xanthines | 2000 |
Oculogyric-like crises in a 92-year-old woman with vascular Parkinsonism.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Brain; Brain Ischemia; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Levodopa; Magnetic Resonance Imaging; Ocular Motility Disorders; Parkinson Disease, Secondary; Treatment Outcome | 2001 |
Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carrier Proteins; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Electrophysiology; Female; Globus Pallidus; Levodopa; Macaca; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease, Secondary; Radioligand Assay | 2001 |
Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions.
Topics: Animals; Autoradiography; Callithrix; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Enkephalins; Female; In Situ Hybridization; Injections, Subcutaneous; Levodopa; Ligands; Male; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Protein Precursors; Putamen; RNA, Messenger; Tritium | 2001 |
Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chlorides; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Ferric Compounds; Immunoenzyme Techniques; Levodopa; Male; Neostriatum; Nerve Net; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2001 |
Parkinsonism after glycine-derivate exposure.
Topics: Antiparkinson Agents; Benserazide; Drug Therapy, Combination; Globus Pallidus; Glycine; Glyphosate; Herbicides; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease, Secondary; Substantia Nigra; Videotape Recording | 2001 |
The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Electromyography; Female; Genes, Recessive; Immunohistochemistry; Indoles; Levodopa; Male; Memory Disorders; Mice; Mice, Inbred C3H; Mice, Neurologic Mutants; Motor Activity; Neurons; Parkinson Disease, Secondary; Postural Balance; Selegiline; Tyrosine 3-Monooxygenase | 2001 |
Symptomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes in the putamen and cerebral white matter: implications for the diagnosis of vascular parkinsonism.
Topics: Aged; Antiparkinson Agents; Brain Infarction; Brain Ischemia; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Muscle Rigidity; Parkinson Disease; Parkinson Disease, Secondary; Putamen; Substantia Nigra | 2001 |
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dependovirus; Disease Models, Animal; Dopamine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Transduction, Genetic | 2001 |
cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum.
Topics: Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Denervation; DNA; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Administration Routes; Enkephalins; Female; Gene Expression; Levodopa; Oligonucleotides, Antisense; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transcription Factor AP-1 | 2001 |
Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adaptation, Physiological; Animals; Autoradiography; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Administration Schedule; Dynorphins; Female; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Knockout; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Receptor, Adenosine A2A; Receptors, Purinergic P1; RNA, Messenger; Substantia Nigra | 2002 |
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Dyskinesia, Drug-Induced; Female; Gait; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Sympatholytics | 2002 |
Dystonia in multiple system atrophy.
Topics: Aged; Brain; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Neurologic Examination; Parkinson Disease, Secondary | 2002 |
Dopa-responsive parkinsonism secondary to right temporal lobe haemorrahage.
Topics: Antiparkinson Agents; Cerebral Hemorrhage; Dominance, Cerebral; Humans; Intracranial Arteriovenous Malformations; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Rupture, Spontaneous; Temporal Lobe | 2002 |
Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia.
Topics: Aged; Antineoplastic Agents; Antiparkinson Agents; Carbidopa; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Levodopa; Male; Parkinson Disease, Secondary; Recombinant Proteins; Treatment Outcome | 2002 |
[Parkinsonism].
Topics: Amantadine; Arteriosclerosis; Genes, Dominant; Guam; Histamine H1 Antagonists; Humans; Levodopa; Middle Aged; Parasympatholytics; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Physical Therapy Modalities; Speech Disorders | 1978 |
Experimental neuropathy with Parkinson-like muscular rigidity. A suitable model for testing dopaminergic agonists and neuroleptic drugs.
Topics: 6-Aminonicotinamide; Animals; Antipsychotic Agents; Baclofen; Brain; Brain Chemistry; Bromocriptine; Central Nervous System Diseases; Disease Models, Animal; Dopamine; Drug Evaluation, Preclinical; Electromyography; Gluconates; Levodopa; Lisuride; Male; Motor Neurons; Muscle Contraction; Niacinamide; Parkinson Disease, Secondary; Rats; Reserpine; RNA; Spinal Cord; Sugar Phosphates | 1978 |
Mortality of patients with Parkinson's disease treated with levodopa.
Topics: Carboxy-Lyases; Drug Synergism; Humans; Levodopa; Life Expectancy; Middle Aged; Parkinson Disease, Secondary; Time Factors | 1977 |
Reversible spastic and pyramidal tract signs in a patient with Parkinson's disease on L-dopa.
Topics: Female; Humans; Levodopa; Middle Aged; Muscle Spasticity; Nervous System Diseases; Parkinson Disease, Secondary; Pyramidal Tracts | 1977 |
Action of dopamine agonists on parkinson-like muscle rigidity induced by 6-aminonicotinamide.
Topics: 6-Aminonicotinamide; Animals; Brain Chemistry; Corpus Striatum; Diencephalon; Dihydroxyphenylalanine; Electromyography; Levodopa; Limbic System; Lisuride; Male; Muscles; Niacinamide; Parkinson Disease, Secondary; Rats; Tyrosine | 1979 |
Enkephalins and nigrostriatal function.
Topics: Animals; Apomorphine; Behavior, Animal; Dextroamphetamine; Endorphins; Enkephalins; Hydroxydopamines; Levodopa; Male; Naloxone; Parkinson Disease; Parkinson Disease, Secondary; Phenethylamines; Rats; Receptors, Opioid; Reserpine; Substantia Nigra | 1978 |
Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats.
Topics: Animals; Apomorphine; Brain; Brain Chemistry; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Hydroxydopamines; Levodopa; Male; Movement; Nerve Degeneration; Neurons; Neurotransmitter Agents; Oxotremorine; Parkinson Disease, Secondary; Rats; Rotation; Stereotaxic Techniques; Substantia Nigra; Synaptic Transmission; Time Factors | 1975 |
Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.
Topics: Adult; Bromocriptine; Carbidopa; Chronic Disease; Humans; Levodopa; Locus Coeruleus; Male; Meperidine; Opioid-Related Disorders; Parkinson Disease, Secondary; Substantia Nigra | 1979 |
[Positive effects of L-dopa on a "marginal" symptomatology observed in parkinsonians].
Topics: Aged; Brain Diseases; Female; Frontal Lobe; Humans; Levodopa; Male; Ophthalmoplegia; Paresthesia; Parkinson Disease, Secondary; Reflex, Babinski | 1978 |
[Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
Topics: Activities of Daily Living; Aged; Amantadine; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hyperkinesis; Levodopa; Long-Term Care; Male; Middle Aged; Motor Activity; Parasympatholytics; Parkinson Disease, Secondary; Therapeutic Equivalency; Time Factors | 1977 |
Hemiparkinsonism. A human model for studying dopaminergic supersensitivity.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Dextroamphetamine; Disease Models, Animal; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease, Secondary; Receptors, Dopamine | 1979 |
Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism.
Topics: Animals; Atropine; Brain; Disease Models, Animal; Dopamine; Forelimb; Hydroxydopamines; Levodopa; Locomotion; Male; Norepinephrine; Parkinson Disease, Secondary; Postural Balance; Rats | 1979 |
[Abnormal movements induced by psychotropic drugs].
Topics: Chorea; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium; Movement Disorders; Parkinson Disease, Secondary; Psychotropic Drugs; Receptors, Dopamine; Receptors, Drug; Tremor | 1979 |
[Neurochemical aspects of Parkinson tremor].
Topics: Antiparkinson Agents; gamma-Aminobutyric Acid; Histamine; Humans; Levodopa; Parkinson Disease, Secondary; Serotonin; Tremor | 1979 |
[Pallido-nigral degeneration--a case of Parkinson's syndrome resistant to L-dopa].
Topics: Aged; Globus Pallidus; Humans; Levodopa; Male; Parkinson Disease, Secondary; Substantia Nigra | 1977 |
Factors influencing the occurrence of "on-off" symptoms during long-term treatment with L-dopa.
Topics: Adult; Aged; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Metoclopramide; Middle Aged; Parkinson Disease, Secondary; Time Factors | 1978 |
Parkinson's disease improvement after the addition of levodopa-carbidopa to anticholinergic treatment. An open controlled study.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease, Secondary; Tremor; Trihexyphenidyl | 1978 |
Dopaminergic agonists in animal models of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Cats; Disease Models, Animal; Haplorhini; Levodopa; Parkinson Disease, Secondary; Piribedil; Rats; Reserpine; Tyrosine | 1975 |
[Hyperuricemia in Parkinson's syndrome--by chance or probable?].
Topics: Adult; Aged; Female; Gout; Humans; Hypertension; Levodopa; Male; Middle Aged; Obesity; Parkinson Disease, Secondary; Sex Factors; Uric Acid | 1976 |
[Experience with a l-dopa retard preparation in the peroral long-term therapy of the Parkinsonian syndrome].
Topics: Administration, Oral; Aged; Amino Acids; Delayed-Action Preparations; Drug Evaluation; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease, Secondary; Personality Assessment; Psychiatric Status Rating Scales | 1976 |
[Characteristics of regional cerebral circulation in parkinsonism patients according the 133Xe clearance findings].
Topics: Adult; Aged; Cerebral Cortex; Cerebrovascular Circulation; Cerebrovascular Disorders; Female; Frontal Lobe; Humans; Infant, Newborn; Levodopa; Male; Middle Aged; Occipital Lobe; Parietal Lobe; Parkinson Disease; Parkinson Disease, Secondary; Xenon Radioisotopes | 1977 |
[Variations of the therapeutic action (on-off phenomenon) in patients with Parkin].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Humans; Levodopa; Parkinson Disease, Secondary | 1977 |
[Parosmia and anosmia under L-dopa therapy (author's transl)].
Topics: Carboxy-Lyases; Humans; Levodopa; Male; Middle Aged; Olfaction Disorders; Parkinson Disease, Secondary; Smell; Time Factors | 1977 |
Biochemical factors in Schizophrenia.
Topics: Amphetamines; Animals; Binding Sites; Brain; Cocaine; Dopamine; Humans; Levodopa; Parkinson Disease, Secondary; Psychoses, Substance-Induced; Receptors, Dopamine; Schizophrenia; Tranquilizing Agents | 1977 |
[Diagnosis and therapy of parkinsonian symptomatology in idiopathic calcification of the basal ganglia. A follow-up study (author's transl)].
Topics: Basal Ganglia; Calcinosis; Female; Humans; Levodopa; Middle Aged; Parkinson Disease, Secondary; Tomography, X-Ray Computed | 1977 |
[Dopamine beta hydroxylase. Value and limits of its study in neurology].
Topics: Amantadine; Cold Temperature; Dopamine beta-Hydroxylase; Epilepsy; Humans; Levodopa; Movement Disorders; Parkinson Disease, Secondary; Quadriplegia | 1976 |
[The effectiveness of amantadine (midantan) in the treatment of the parkinsonian syndrome].
Topics: Amantadine; Arteriosclerosis; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary | 1976 |
[Review of problems in the treatment of the parkinsonian syndrome with L-dopa].
Topics: Arrhythmias, Cardiac; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Hypertension; Hypotension, Orthostatic; Levodopa; Movement Disorders; Parkinson Disease, Secondary; Psychoses, Substance-Induced | 1976 |
[Modern antiparkinsonics (L-dopa and amantadine) and presentday psychiatry (author's transl)].
Topics: Amantadine; Humans; Levodopa; Mental Disorders; Parkinson Disease, Secondary; Psychotic Disorders | 1976 |
[Combined treatment of Parkinsonism with levopa, midantan and anticholinergic drugs].
Topics: Acetylcholine; Adult; Aged; Amantadine; Antiparkinson Agents; Cholinesterases; Drug Therapy, Combination; Female; Humans; Intracranial Arteriosclerosis; Levodopa; Male; Middle Aged; Muscle Tonus; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Trihexyphenidyl | 1976 |
Persistent parkinsonism following neuroleptanalgesia.
Topics: Adolescent; Anesthesia, Inhalation; Anesthesia, Intravenous; Droperidol; Female; Fentanyl; Humans; Levodopa; Neuroleptanalgesia; Nitrous Oxide; Parkinson Disease; Parkinson Disease, Secondary; Propranolol; Tooth Extraction; Tooth, Impacted | 1975 |
Relationship between animal models and clinical parkinsonism.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Humans; Levodopa; Norepinephrine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Reserpine; Substantia Nigra | 1975 |
[Letter: Malignant melanoma during treatment with levodopa].
Topics: Aged; Biopsy; Humans; Levodopa; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Parkinson Disease, Secondary; Skin Neoplasms | 1975 |
[L-dopa + peripheral decarboxylase antagonist].
Topics: Carboxy-Lyases; Drug Combinations; Humans; Levodopa; Parkinson Disease, Secondary | 1975 |
The treatment of parkinsonism.
Topics: Amantadine; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary | 1975 |
[The role of disorders of "non-specific systems" of the brain in the pathogenesis of the Parkinsonian syndrome].
Topics: Brain Diseases; Electroencephalography; Electromyography; Humans; Hypnosis; Levodopa; Middle Aged; Parkinson Disease, Secondary; Psychopathology; Reticular Formation; Sleep Stages; Wakefulness | 1975 |
[Biochemical-pharmacological basis for the clinical use of L-dioxypheny alanine in Parkinson's syndrome].
Topics: Blood-Brain Barrier; Brain; Dopamine; Humans; Levodopa; Parkinson Disease, Secondary | 1975 |
[Clinical and biochemical considerations on depressive states occuring during parkinsonian syndrome treated by L-Dopa].
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Catecholamines; Depression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary | 1976 |
Levodopa challenge test in Parkinson's disease.
Topics: Apomorphine; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1992 |
Parkinsonism associated with calcium channel blockers: a prospective follow-up study.
Topics: Adrenergic beta-Antagonists; Aged; Calcium Channel Blockers; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease, Secondary; Prognosis; Prospective Studies | 1992 |
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
Topics: Aged; Apomorphine; Chlorpromazine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electromyography; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Sulpiride | 1992 |
Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced hemiparkinsonism on the kinematics of a two-dimensional,multijoint arm movement in the rhesus monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arm; Behavior, Animal; Carbidopa; Female; Levodopa; Macaca mulatta; Male; Movement; Parkinson Disease, Secondary; Reaction Time; Substantia Nigra; Tyrosine 3-Monooxygenase | 1992 |
Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Catecholamines; Dopamine; Dopamine Agents; Levodopa; Macaca fascicularis; Male; Mazindol; Parkinson Disease, Secondary; Receptors, Dopamine | 1992 |
Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Dopamine Agents; Ergolines; Female; Levodopa; Male; Movement; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1992 |
Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa.
Topics: Animals; Behavior, Animal; Histocytochemistry; Injections, Intraventricular; Levodopa; Male; Nerve Degeneration; Parkinson Disease, Secondary; Psychomotor Performance; Rats; Rats, Sprague-Dawley; S-Adenosylmethionine; Substantia Nigra; Tremor; Tyrosine 3-Monooxygenase | 1992 |
Blockade of N-methyl-D-aspartate receptors potentiates dopaminergic responses in the 6-OHDA model of Parkinson: differential role of D-1 and D-2 receptors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Dizocilpine Maleate; Dopamine; Drug Synergism; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate | 1992 |
[Physical therapy and speech therapy in Parkinson syndrome--a status assessment].
Topics: Aged; Combined Modality Therapy; Dementia; Disability Evaluation; Female; Humans; Levodopa; Male; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Parkinson Disease, Secondary; Physical Therapy Modalities; Quality of Life; Speech Therapy | 1992 |
[A case at Salpêtrière hospital November 1990. Parkinson syndrome with poor response to dopa therapy in a 64 year-old man].
Topics: Atrophy; Corpus Striatum; Diagnosis, Differential; Drug Resistance; Humans; Levodopa; Male; Middle Aged; Olivopontocerebellar Atrophies; Parkinson Disease, Secondary; Substantia Nigra; Supranuclear Palsy, Progressive | 1992 |
Effect of estrogen and progesterone on L-dopa induced dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Estradiol; Female; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Progesterone | 1992 |
L-dopa abuse in a patient with former alcoholism.
Topics: Adult; Alcoholism; Humans; Levodopa; Male; Parkinson Disease, Secondary; Substance-Related Disorders | 1992 |
[Parkinsonism following addition of fluoxetine to treatment with neuroleptics or carbamazepine].
Topics: Depression; Female; Fluoxetine; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary | 1992 |
Estimation of regional cerebral utilization of [11C]-L-3,4-dihydroxy-phenylalanine (DOPA) in the primate by positron emission tomography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Corpus Striatum; Dopamine; Female; Levodopa; Macaca mulatta; Parkinson Disease, Secondary; Radiochemistry; Structure-Activity Relationship; Tomography, Emission-Computed | 1992 |
Emerging perspectives in Parkinson's disease.
Topics: Animals; Humans; Levodopa; MPTP Poisoning; Neurology; Parkinson Disease; Parkinson Disease, Secondary; Selegiline | 1992 |
[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Parkinson Disease, Secondary | 1992 |
Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys.
Topics: Animals; Dizocilpine Maleate; Drug Combinations; Drug Synergism; Dystonia; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Reference Values; Saimiri | 1992 |
Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Par
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; In Vitro Techniques; Isoproterenol; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Receptors, Adrenergic, beta; Synapses | 1991 |
The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.
Topics: Animals; Dopamine; Female; Globus Pallidus; Levodopa; Macaca mulatta; MPTP Poisoning; Parkinson Disease, Secondary; Quinoxalines; Rats; Receptors, AMPA; Receptors, Neurotransmitter; Synaptic Transmission | 1991 |
Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
Topics: Animals; Dopamine Agents; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary | 1991 |
Early onset parkinsonism in Chinese.
Topics: Adolescent; Adult; Age Factors; China; Circadian Rhythm; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Parkinson Disease, Secondary | 1991 |
Consideration on two cases of dystonia-parkinsonism.
Topics: Carbidopa; Child; Dystonia; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Parkinson Disease, Secondary | 1991 |
The apomorphine test in parkinsonian syndromes.
Topics: Aged; Apomorphine; Diagnosis, Differential; Female; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Muscular Atrophy; Neurologic Examination; Olivopontocerebellar Atrophies; Parkinson Disease; Parkinson Disease, Secondary; Prognosis; Supranuclear Palsy, Progressive | 1991 |
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Callithrix; Disease Models, Animal; Drug Synergism; Ibotenic Acid; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 1991 |
Apomorphine test in parkinsonian syndromes.
Topics: Apomorphine; Humans; Levodopa; Parkinson Disease, Secondary | 1990 |
Modulatory role for CCK-B antagonists in Parkinson's disease.
Topics: Animals; Benzodiazepinones; Carbidopa; Cholecystokinin; Devazepide; Dopamine Agents; Levodopa; Male; Motor Activity; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Phenylurea Compounds; Receptors, Cholecystokinin; Saimiri | 1990 |
MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benserazide; Dizocilpine Maleate; Dopamine Agents; Ergolines; Hydroxydopamines; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereoisomerism; Stereotyped Behavior | 1990 |
Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callitrichinae; Dopamine; Dopamine Agents; Excitatory Amino Acid Antagonists; Female; Levodopa; Male; Neurotransmitter Agents; Parasympathomimetics; Parkinson Disease, Secondary; Receptors, Neurotransmitter; Serotonin Antagonists | 1990 |
[Parkinsonian syndrome. Etiology, diagnosis, treatment].
Topics: Dopamine Agents; Humans; Levodopa; Parasympatholytics; Parkinson Disease, Secondary | 1990 |
Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior, Animal; Benserazide; Biopterins; Brain; Dopamine; Female; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Saimiri; Time Factors; Tissue Distribution; Tyrosine 3-Monooxygenase | 1990 |
Apparent unilateral visual neglect in MPTP-hemiparkinsonian monkeys is due to delayed initiation of motion.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Attention; Behavior, Animal; Female; Levodopa; Macaca fascicularis; Macaca mulatta; Motor Activity; Parkinson Disease, Secondary; Reaction Time; Visual Perception | 1991 |
Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Neurologic Examination; Parkinson Disease, Secondary; Stereotyped Behavior | 1991 |
Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates.
Topics: Acetylcarnitine; Animals; Carbidopa; Caudate Nucleus; Electroretinography; Female; Homovanillic Acid; Immunohistochemistry; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary; Substantia Nigra | 1991 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Benzazepines; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Saimiri | 1990 |
Hemiparkinsonism-hemiatrophy syndrome: clinical and neuroradiologic features.
Topics: Adolescent; Adult; Atrophy; Brain; Extremities; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease, Secondary; Retrospective Studies; Syndrome; Tomography, X-Ray Computed | 1990 |
Interference of 3-O-methyldopa with L-dopa treatment for MPTP-induced parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Injections, Intravenous; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Receptors, Dopamine; Tyrosine | 1990 |
Dopa-responsive parkinsonism with normal 6[18F]-fluorodopa positron emission tomography scans.
Topics: Corpus Striatum; Fluorine Radioisotopes; Humans; Levodopa; Manganese; Parkinson Disease, Secondary; Substantia Nigra; Tomography, Emission-Computed | 1990 |
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Brain; Brain Chemistry; Bromocriptine; Dopamine; Female; Homovanillic Acid; Kinetics; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Receptors, Dopamine; Spiperone | 1990 |
Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Body Weight; Corpus Striatum; Disease Models, Animal; Dopamine; Hydrazines; Levodopa; Male; Methyltyrosines; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease, Secondary; Receptors, Dopamine; Stereotyped Behavior | 1990 |
The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Carbidopa; Corpus Striatum; Deoxyglucose; Flunitrazepam; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Macaca fascicularis; Neurons; Organ Specificity; Parkinson Disease; Parkinson Disease, Secondary; Tritium | 1990 |
Induction of chorea and dystonia in parkinsonian primates.
Topics: Animals; Chorea; Dystonia; Levodopa; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary | 1990 |
Levodopa-responsive parkinsonism following central herniation due to bilateral subdural hematomas.
Topics: Aged; Encephalocele; Hematoma, Subdural; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary; Tomography, X-Ray Computed | 1990 |
CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary; Saimiri; Sincalide | 1990 |
Which risk factors predict the levodopa response in fluctuating Parkinson's disease?
Topics: Adult; Aged; Humans; Levodopa; Middle Aged; Parkinson Disease, Secondary; Regression Analysis; Risk Factors | 1990 |
Variation of therapeutic response in Parkinson's disease: a retrospective study.
Topics: Age Factors; Aged; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Regression Analysis; Retrospective Studies | 1990 |
Bromocriptine blood levels after the concomitant administration of levodopa, amantadine and biperiden in Parkinson's disease.
Topics: Administration, Oral; Aged; Amantadine; Biperiden; Bromocriptine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Piperidines | 1990 |
Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Brain; Bromocriptine; Catecholamines; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Prolactin; Pyridines | 1986 |
Apomorphine test for dopaminergic responsiveness.
Topics: Apomorphine; Diagnosis, Differential; Double-Blind Method; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1989 |
Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Analgesics; Animals; Callitrichinae; Dopamine Agents; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Phenanthridines; Pyridines | 1989 |
Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergolines; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Quinpirole | 1989 |
NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinson Disease, Secondary; Prodrugs; Saimiri; Time Factors | 1989 |
[Tetrahydroisoquinoline and parkinsonism].
Topics: Animals; Chemical Phenomena; Chemistry; Female; Isoquinolines; Levodopa; Male; Mice; Motor Activity; Parkinson Disease, Secondary; Saimiri; Tetrahydroisoquinolines | 1989 |
Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey.
Topics: Animals; Aspartic Acid; Dibenzocycloheptenes; Dizocilpine Maleate; Injections, Intramuscular; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; N-Methylaspartate; Parkinson Disease, Secondary | 1989 |
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dose-Response Relationship, Drug; Ergolines; Injections, Intravenous; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Quinpirole; Stereotyped Behavior | 1989 |
Madopar HBS and the decompensated phase of Parkinson disease.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary | 1989 |
The effects of oral protein on the absorption of intraduodenal levodopa and motor performance.
Topics: Aged; Dietary Proteins; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease, Secondary | 1989 |
Timing of levodopa therapy: evidence from MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Levodopa; Macaca fascicularis; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Time Factors | 1987 |
Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
Topics: Aged; Animals; Antiparkinson Agents; Brain; Enkephalin, Leucine; Female; Humans; Hydroxydopamines; Levodopa; Male; Middle Aged; MSH Release-Inhibiting Hormone; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Stereotyped Behavior | 1987 |
MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Droxidopa; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Pyridines; Receptors, Muscarinic; Somatostatin | 1987 |
Coexistent tardive dyskinesia and parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Reserpine; Tetrabenazine | 1987 |
Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.
Topics: Adult; Aged; Antipsychotic Agents; Benserazide; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Psychotic Disorders; Trihexyphenidyl | 1988 |
Antiparkinsonian activity of a single oral dose of PHNO.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease, Secondary; Reaction Time | 1987 |
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Oxazines; Parkinson Disease, Secondary; Pyridines | 1988 |
Levodopa addiction. A case study.
Topics: Adult; Dermatitis, Seborrheic; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Muscle Rigidity; Paranoid Disorders; Parkinson Disease, Secondary; Psychoses, Substance-Induced; Risk Factors; Substance Withdrawal Syndrome; Substance-Related Disorders | 1988 |
[L-threo-DOPS therapy and parkinsonism].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Antiparkinson Agents; Brain; Dopamine; Droxidopa; Humans; Levodopa; Norepinephrine; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Serine; Stereotaxic Techniques | 1986 |
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Humans; Indans; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Selegiline; Structure-Activity Relationship; Tyramine | 1987 |
Clinical effects of L-threo-3,4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia.
Topics: Adult; Aged; Antiparkinson Agents; Droxidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Parkinson Disease, Secondary; Serine; Shy-Drager Syndrome | 1987 |
[Clinical aspects and pathogenesis of the "on-off" phenomenon in Parkinson syndrome].
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease, Secondary; Risk Factors | 1988 |
[A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carbidopa; Disease Models, Animal; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Movement Disorders; Parkinson Disease, Secondary; Pyridines | 1985 |
Metabolic mapping of the oculomotor system in MPTP-induced parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Eye Movements; Female; Glucose; Levodopa; Macaca mulatta; Male; Oculomotor Muscles; Parkinson Disease, Secondary; Pyridines | 1988 |
Amine fluorescence histochemical investigation of the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced parkinsonian mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Histocytochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Parkinson Disease, Secondary; Pyridines | 1988 |
Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Electroretinography; Evoked Potentials, Visual; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines; Time Factors | 1988 |
Possible treatment of Parkinson's disease with intrathecal medication in the MPTP model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Homovanillic Acid; Infusion Pumps; Injections, Spinal; Levodopa; Parkinson Disease, Secondary; Pyridines; Time Factors | 1988 |
A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Equipment Design; Feeding Behavior; Levodopa; Macaca fascicularis; Male; Movement; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine | 1988 |
Bromocriptine therapy in striatonigral degeneration.
Topics: Aged; Bromocriptine; Humans; Levodopa; Male; Nerve Degeneration; Parkinson Disease, Secondary; Putamen; Substantia Nigra | 1988 |
Mood swings associated with the 'on-off' phenomenon in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Parkinson Disease; Parkinson Disease, Secondary | 1987 |
Update on Parkinson disease.
Topics: Animals; Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 1987 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Rats | 1986 |
Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Brain; Brain Chemistry; Carbidopa; Carotid Artery, Internal; Disease Models, Animal; Dominance, Cerebral; Dopamine; Homovanillic Acid; Injections, Intra-Arterial; Levodopa; Macaca fascicularis; Movement; Neurons; Parkinson Disease, Secondary; Pyridines | 1986 |
Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Bromocriptine; Butyrophenones; Female; Kinetics; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Spiperone; Time Factors | 1986 |
MPTP toxicity: clinical features.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Bromocriptine; California; Chemical Industry; District of Columbia; Female; Humans; Levodopa; Male; Occupational Diseases; Parkinson Disease, Secondary; Pyridines | 1986 |
Development of new pharmacological approaches in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cysteinyldopa; Delayed-Action Preparations; Dopamine; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Structure-Activity Relationship | 1987 |
Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkey; mechanographic and electromyographic data.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Parkinson Disease, Secondary; Pyridines | 1986 |
Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines | 1987 |
Biochemical and behavioral correction of MPTP Parkinson-like syndrome by fetal cell transplantation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Fetus; Levodopa; Macaca mulatta; Mesencephalon; Motor Activity; Parkinson Disease, Secondary; Pyridines | 1987 |
Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Female; Glucose; Levodopa; Macaca mulatta; Male; Parkinson Disease, Secondary; Pyridines; Tissue Distribution | 1987 |
Sudden onset of confusion with severe exacerbation of parkinsonism during levodopa therapy.
Topics: Aged; Carbidopa; Cognition Disorders; Confusion; Dose-Response Relationship, Drug; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease, Secondary | 1986 |
Parkinsonism induced by high-dose cytosine arabinoside.
Topics: Carbidopa; Cytarabine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Leukemia, Myelomonocytic, Acute; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1987 |
Sudden confusion with levodopa withdrawal.
Topics: Cognition Disorders; Confusion; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Secondary; Substance Withdrawal Syndrome | 1987 |
[Features of affective disorders in patients with vascular parkinsonism].
Topics: Aged; Anxiety; Cerebrovascular Disorders; Depression; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Mood Disorders; Parasympatholytics; Parkinson Disease, Secondary | 1987 |
[Modelling of the parkinsonian syndrome by the administration of kainic acid into the caudate nucleus].
Topics: Animals; Caudate Nucleus; Disease Models, Animal; Drug Evaluation, Preclinical; Electrodes, Implanted; Electroencephalography; Female; Injections; Kainic Acid; Levodopa; Male; Parkinson Disease, Secondary; Rats; Time Factors; Trihexyphenidyl | 1987 |
Current status of levodopa therapy in idiopathic Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Humans; Levodopa; Middle Aged; Parkinson Disease, Secondary; Time Factors | 1987 |
Response of tardive and L-dopa-induced dyskinesias to antidepressants.
Topics: Aged; Antidepressive Agents; Depressive Disorder; Desipramine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Trazodone | 1987 |
[Experience with the use of parlodel in the treatment of Parkinson patients].
Topics: Adult; Aged; Bromocriptine; Drug Therapy, Combination; Female; Humans; Hypoxia, Brain; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary | 1986 |
[Therapy of Parkinson syndrome].
Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease, Secondary | 1986 |
Long-term course in Parkinson's syndrome and cerebral polypathy (Parkinson plus).
Topics: Brain Damage, Chronic; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Motor Skills; Parkinson Disease; Parkinson Disease, Secondary; Tomography, X-Ray Computed | 1987 |
[Current status of conservative therapy of extrapyramidal movement disorders in childhood and adolescence].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Autogenic Training; Basal Ganglia; Basal Ganglia Diseases; Brain Damage, Chronic; Child; Child, Preschool; Education, Special; Electroencephalography; Female; Follow-Up Studies; Humans; Levodopa; Male; Muscle Hypertonia; Parkinson Disease, Secondary; Psychotropic Drugs; Risk; Tic Disorders | 1985 |
Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Amines; Brain Chemistry; Bromocriptine; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Movement; Parkinson Disease, Secondary; Pyridines | 1985 |
A simple quantitative bradykinesia test in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Disease Models, Animal; Dopamine; Levodopa; Mice; Mice, Inbred C57BL; Motor Activity; Norepinephrine; Parkinson Disease, Secondary; Pyridines | 1985 |
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Benserazide; Benzazepines; Callitrichinae; Levodopa; Male; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Tremor | 1985 |
Major depression and carbon monoxide-induced parkinsonism: diagnosis, computerized axial tomography, and response to L-dopa.
Topics: Adult; Antidepressive Agents, Tricyclic; Carbon Monoxide Poisoning; Depressive Disorder; Globus Pallidus; Humans; Levodopa; Male; Necrosis; Parkinson Disease, Secondary; Tomography, X-Ray Computed | 1985 |
[Useful data on parkinsonian syndromes].
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease, Secondary | 1985 |
Stereotactic thalamotomy and L-dopa induced involuntary movement in Parkinsonism.
Topics: Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease, Secondary; Thalamus | 1973 |
[Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Diphenhydramine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Histamine H1 Antagonists; Levodopa; Parasympatholytics; Parkinson Disease, Secondary; Trihexyphenidyl | 1974 |
[The problem of side effects after a treatment with L-dopa in the Parkinson's syndrome: clinical and animal studies (author's transl)].
Topics: Adult; Aged; Brain; Cardiovascular Diseases; Dopamine; Drug Eruptions; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Pain; Paresthesia; Parkinson Disease, Secondary; Psychoses, Substance-Induced | 1974 |
[Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood-Brain Barrier; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease, Secondary; Time Factors | 1974 |
Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Drinking Behavior; Electric Stimulation; Electromyography; Feeding and Eating Disorders; Feeding Behavior; Humans; Hydroxydopamines; Levodopa; Motor Neurons; Muscle Contraction; Nerve Degeneration; Neural Pathways; Parkinson Disease; Parkinson Disease, Secondary; Perceptual Disorders; Rats; Reflex, Stretch; Substantia Nigra | 1974 |